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Transmissible Spongiform Encephalopathies (TSEs), also known as prion diseases, 
are a group of progressive fatal neurological diseases whose incidence increases 
substantially with age. To date, the etiology of TSEs remains ill-defined. It is believed 
that the key pathogenic event in all prion diseases, whether inherited, infectious or 
sporadic, is the conformational conversion of a host-encoded prion protein (PrPC) to 
the scrapie isoform (PrPSc). However, the clinical and histopathological presentations 
of prion diseases are heterogeneous, depending not only on the strains of PrPSc but 
also on the mode of disease acquisition, such as age-related sporadic versus infectious 
prion diseases. Accumulated evidence suggests that the highly conserved N-linked 
glycans on PrPC are important in disease phenotype. Thus, a better understanding of 
the nature of the N-linked glycans on PrPC during the normal ageing process may 
provide insights into the roles that these N-linked glycans play in the pathogenesis of 
prion diseases. In this study, three lines of evidence from PrPC glycan profiling 
suggest that ageing and prion diseases are closely related. Firstly, Western blotting 
with anti-PrP antibodies and endoglycosidase treatment showed enhanced expression 
of underglycosylated (mono- and un-glycosylated) full length PrPC and N-terminally 
truncated PrPC with increased age. Similar results were also reported in scrapie 
infection. Secondly, lectin-binding assay revealed increased complex sugar formation 
on ageing full length PrPC, consistent with those observations on PrPSc derived from 
the scrapie-infected Syrian hamster brain. Thirdly, simplification of the glycosylation 
process was observed on ageing truncated PrPC. This suggests possible ER retention 
and consequent aggregation, corroborating previously reported prion-associated 
proteasomal impairment. Given the ability of prion strains to consistently propagate 
distinct strain-specified properties, these results suggest that age-related changes in 
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PrPC glycosylation may render certain pools of glycosylated PrPC more susceptible to 
PrPSc conversion than others, and strengthen the involvement of PrP glycosylation in 
prion disease development. 
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1.1 AGEING AND NEURODEGENERATION 
Etymologically, the word ageing refers to the process of growing older and showing 
the effects of increasing age, often manifested by health deterioration. In greying 
populations including Singapore, the prevalence of certain age-related diseases such 
as cardiovascular disease, cancer, diabetes, stroke and neurodegeneration (Halliwell 
and Gutteridge 1999; Chang and Halter 2003; Li et al. 2005) is on the rise. In 2003, 
7.7% of residents in Singapore are elderly individuals aged 65 years and above (Heng 
and Png 2004). Over the years, the number and proportion of individuals aged 85 
years and above has more than doubled, and these figures continue to increase with an 
annual growth of 3.6% (Ang and Lee 2000). The prevalence of stroke, which is linked 
to increased risk of dementia, is 3.65% among Singaporeans aged 50 years and above 
(Venketasubramanian et al. 2005), and this occurrence increases exponentially with 
age. The stroke incidence among those aged between 50-54 years was 0.67% while 
that among those aged 85 years and above was 14.86%. 
 
The prevalence of neurodegenerative disorders such as Parkinson’s disease (PD) in 
individuals aged 50 years and above is 0.3% (Tan et al. 2004). A random sampling of 
200 elderly Chinese and 149 elderly Malay residents in Singapore showed that the 
incidence of Alzheimer’s disease (AD) is 2% (Kua and Ko 1995) and that both ethnic 
groups displayed similar rates of AD prevalence. The occurrence of 
neurodegenerative diseases by percentage is comparatively lower, but given our 4.5 
million population, the absolute numbers are still alarming. The social and economic 
implications of these age-related diseases would be devastating if left unchecked, 
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especially given the growing age-dependency ratio of 10.7 aged per 100 residents 
aged 15-64 years (Heng and Png 2004). 
 
Neurodegenerative diseases encompass a large group of neurological defects with 
diverse clinical and pathological expressions, affecting specific subsets of neurons in 
specific regions of the central nervous system. Neurodegeneration is one of the most 
heavily researched subjects in the field of gerontology due in part to its economic and 
medical implications on the society. Furthermore, nervous system disorders are ideal 
models of ageing because neurons obey the Hayflick Limit Theory in most brain 
regions (Bhardwaj et al. 2006; Rakic 1985) and may thus represent whole organism 
ageing on a micro-level. In keeping with this, Tanner (1992) reported that increasing 
age is a definite risk factor for neurodegenerative disease.  
 
Neuropathological changes are consistently observed in most, if not all, 
neurodegenerative disorders such as AD, PD and prion diseases. These changes 
include extensive loss of functional neurons, reactive gliosis and accumulation of 
misfolded proteins (Ross and Poirier 2004). Consequently, these could trigger motor 
and cognitive impairment as seen in PD and AD (Gerhardt et al. 2002; Forno 1996; 
Sulkava et al. 1983). Ultimately, almost all neurodegenerative diseases are fatal. 
 
Despite the efforts put into studying neurodegeneration, the causes of the majority of 
these debilitating diseases remain unknown. Even in cases where the causative agents 
have been identified, the means by which they trigger the disease is unclear. For 
instance, while the aetiology of prion disease was identified about two decades ago, it 
remains uncertain how a conformationally distinct isoform of prion protein (PrP) 
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triggers the disease. To date, there are no effective therapeutic agents available to 
alleviate the disease symptoms and halt the degenerative progression. Hence the 
greatest challenge to neuroscientists is not only to decipher the causes and 
mechanisms underlying such neuronal cell death but more importantly to develop 
novel therapies against these fatal diseases.  
1.2 TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY / PRION 
DISEASE 
Transmissible Spongiform Encephalopathies (TSEs), also known as prion diseases, 
encompass a group of progressive fatal neurological diseases sharing a common 
neuropathological hallmark – PrP amyloid. In animals, they include scrapie in sheep 
and goats, and bovine spongiform encephalopathy (BSE) in cattle. Kuru, Creutzfeldt-
Jakob Disease (CJD) and Gerstmann-Sträussler-Scheinker (GSS) are the human 
equivalents. These diseases are chronic and fatal in nature with prolonged incubation 
periods before phenotypic changes become visible. As a result, clinical diagnosis 
occurs at a stage when disease prognosis becomes poor. Affected individuals often 
display canonical symptoms such as loss of motor control (ataxia), personality 
changes and severe mental impairment (dementia). Contraction of this disease leads to 
morbidity (Collinge 2001). Post mortem analysis revealed vacuolation of the brain 
resulting from neuron degeneration, astrogliosis as glial cells grow larger in response 
to neuronal damage, and protein accumulation and deposition as amyloid plaques 




Figure 1: Histopathological characteristics of prion disease 
The histo-pathological features of human prion disease include (A) spongiform 
changes due to formation of vacuoles, (B) amyloid plaques formation, and (C) 




Sporadic CJD is the most common form of human prion disease, mostly affecting 
individuals >65 years old. It occurs in about 0.5 to1.5 cases per million people 
worldwide per year (Johnson and Gibbs 1998). Familial CJD, associated with 
mutations within the prion protein encoding gene (Prnp), accounts for approximately 
10-15% of all cases of human prion disease and iatrogenic CJD, transmitted by 
dietary exposure or infection with tainted tissues, accounts for < 1% (Prusiner 1989). 
In Singapore, there are a few documented cases (Lee et al. 1998; See et al. 2004). 
However, this number is likely to be under-reported due to the lack of appropriate 
medical expertise in diagnosis. In the past two decades, CJD has gained widespread 
interest due to growing incidence of a new variant affecting younger individuals, and 
scientifically due to the fact that prions are transmissible despite only being a protein. 
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This is unlike common infectious pathogens such as viruses and bacteria which 
comprise nucleic acids. Secondly, there was extensive media coverage of the spread 
of BSE outside the UK in the 1980s as well as the threat of BSE transmission to 
humans leading to the development of variant CJD (vCJD). It was shown that vCJD 
exhibits unique neuropathological features, such as PrP plaques surrounded by a zone 
of spongiform change, which are not seen in sporadic CJD but which have previously 
been described in scrapie (Will et al. 1996). In line with this, it was shown that Kuru 
and scrapie exhibit neuropathogenic similarities such as neuronal degeneration, 
astrocytosis with little, if any, inflammation and vacuolated neurons (Hadlow 1995). 
Furthermore, it was also shown that Kuru and CJD are transmissible to chimpanzees 
upon intracerebral passage with human brain tissue from these affected individuals 
(Gajdusek et al. 1967a, b; Gibbs et al. 1968).  
 
1.3 PRION PROTEIN 
The aetiology of prion disease remains hitherto ill-defined. The atypical biochemical 
properties of the TSE agent, being resistant to ultraviolet radiation which breaks down 
nucleic acids, led Alper and Griffith to speculate that the causative agent of TSE 
could be a protein (Alper et al. 1967; Griffith 1967). However, it was only 15 years 
later before the true nature of the TSE infectivity was uncovered (Bolton et al. 1982; 
Prusiner et al. 1982b; McKinley et al. 1983).  
 
Prusiner proposed the term Prion to represent “small proteinaceous infectious 
particles which are resistant to inactivation by most procedures that modify nucleic 
acids” (Prusiner 1982a). However, the idea of the infectious TSE agent as being 
comprised solely of protein was not widely accepted as common infectious pathogens 
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comprise nucleic acids. Attempts to isolate PrP showed that it normally resides in 
lipid rafts (McKinley et al. 1983). cDNA sequencing and anti-PrP antibody studies 
found that the same chromosomal gene encodes a normal cellular isoform of PrP 
(denoted as PrPC) as well as PrPSc [scrapie (TSE disease) associated PrP] (Basler et al. 
1986). PrPC is rich in α-helices, protease sensitive and detergent soluble (Figure 2). 
During TSE pathogenesis, PrPC is believed to undergo a conformational change into a 
β-sheet rich PrPSc that is insoluble in detergent and partially resistant to proteinase K 
digestion. However, the process by which this occurs is unknown. Proteinase K (PK) 
treatment of PrPSc results in the persistence of a core molecule, referred to as PrP 27-
30, consisting predominantly of amino acid residues 89-230 (of murine PrP) (Oesch et 
al. 1985) (Figure 3). Prusiner and colleagues also showed that PrPSc polymerizes into 
amyloid fibrils, deposited in amyloid plaques found in the brains of affected 
individuals (Bendheim et al. 1984; DeArmond et al. 1985).  
  
 High α-helical content 
 Proteinase K sensitive 
 Detergent soluble 
 High β-sheet content 
 Partial Proteinase K resistance 
 Detergent insoluble 
 
Figure 2: Tertiary structure of prion protein isoforms 
(A) NMR structure of recombinant PrP (recPrP) residues 90-231 (Syrian hamster 
sequence) showing three α-helices and two small β-strands. Presumably, the structure 
of the α-helical form of recPrP resembles that of PrPC. recPrP (90-231) is viewed 
from the interface where PrPSc is thought to bind to PrPC, leading to PrPSc propagation. 
α-helices A (residues 144-157), B (residues 172-193) and C (residues 200-227) are 
shown in blue; loops in yellow; and β-strands 1 (residues 129-134) and 2 (residues 
159-165) in green. (B) Model of a monomer of PrP 27-30 featuring a left-handed β-





Figure 3: Prion protein isoforms 
Bar diagram of Syrian hamster PrP, which consists of 254 amino acids. Attached 
carbohydrate (CHO) and a glycosyl-phosphatidylinositol (GPI) anchor are indicated. 
After processing of the NH2 and COOH termini, both PrPC and PrPSc consist of 209 
residues. After limited proteolysis, the NH2 terminus of PrPSc is truncated to form PrP 
27-30, which is composed of approximately 142 amino acids. (Extracted from 
Prusiner 1998) 
 
Recent support for the “protein only” hypothesis was provided by Legname and 
colleagues (2004) showing that in vitro produced truncated mouse recombinant PrP 
(89-230), refolded into a β-sheet conformation, was capable of inducing prion 
disease-like neuropathology when introduced intracerebrally into transgenic mice 
over-expressing the mouse prion protein (89-231). In addition, brain extracts from 
these infected mice were transmissible to other mice. Another support was provided 
by Castilla and co-workers (2005) demonstrating the in vitro amplification of 
misfolded PrP and its consequent magnification of TSE infectivity. However, despite 
the growing body of work supporting the prion hypothesis, scepticism still surrounds 
the idea that the infectious agent is “protein only”. The root of this stems from 
phenotypic variations amongst the many strains of TSE identified and the enigmatic 
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feasibility of a single protein encoding such heritable biological information. 
Potentially, the capability of PrPSc to adopt distinct conformations, encrypting 
different strain-specified properties (Telling et al. 1996), can explain this phenomenon. 
In addition, given the close correlation between TSE strain and various PrP 
glycoforms, differential PrP glycosylation may describe how these different PrP 
conformations arose.  
 
PrPC has two highly conserved N-linked glycosylation sites (Asn181-Ile-Thr and 
Asn197-Phe-Thr of human PrP; asparagine residues 180 and 196 of murine PrP) 
(Locht et al. 1986; Kretzschmar et al. 1986b) where high-mannose type 
oligosaccharides are attached in the endoplasmic reticulum (ER). Further processing 
of PrPC occurs as it is trafficked through the Golgi apparatus, leading to glycan 
modifications that include complex sugar types. It was reported that high-mannose 
PrPC glycoforms were preferentially converted to PrPSc in scrapie-infected 
neuroblastoma cells (Winklhofer et al. 2003). Both PrPC and PrPSc glycosylation sites 
are variably glycosylated in vivo, producing un-, mono- and di-glycosylated forms of 
the protein. Additional post-translational processing of PrP involves endoproteolytic 
cleavage of the protein between amino acid residues 111/112 (Chen et al. 1995), 
resulting in amino-terminally truncated forms of the protein.  
 
Numerous studies have shown that prion strains present distinct disease phenotypes. 
Pathologically, these include the incubation time and the lesion profiles upon 
inoculation to mice (Bruce 2003). Biochemically, prion strains may be defined by the 
electrophoretic mobility and glycoform pattern of PrP 27-30 after PK digestion. The 
relative ratio of di-, mono- and un-glycosylated PrP presented has been widely used as 
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differential markers of the disease (Kascsak et al. 1985; Kascsak et al. 1991; Collinge 
et al. 1996; Hill et al. 1997; Wadsworth et al. 1999). Based mainly on the 
electrophoretic mobility, it was found that there were two types of PrPSc (Parchi et al. 
1996). PrPSc type 1 correspond to relative molecular mass (Mr) of ~21,000 while 
PrPSc type 2 correspond to Mr of ~19,000. Both these groups were seen in sCJD. Most 
iCJD samples displayed PrPSc type 1 characterisitics while kuru displayed PrPSc type 
2. nvCJD forms a sub-type of PrPSc type 2 since it shared the electrophoretic mobility 
of PrPSc type 2 but differed in its glycoform pattern from the other forms of CJD with 
type 2 forms of PrPSc. Collinge and co-workers (1996) showed that these two PrPSc 
types can be further separated into four types based on both the electrophoretic 
mobilities and ratio of differently glycosylated PrPSc isoforms after PK treatment 
(Figure 4).  
 
 
Figure 4: Scheme illustrating a classification of prion strains  
The above classification was first described by Collinge and co-workers. Different 
proteinase K fragment sizes and glycoform profiles (di-, mono- and non-glycosylated 
forms) are observed by western blotting in CJD of various origins, sporadic, 
iatrogenic and the variant, this latter being of the same type as the BSE strain. 





To date, the biological function of PrP remains an enigma. Transgenic mice 
homozygous for disrupted PrP gene were found to develop and behave normally, and 
no immunological defects were detected (Bueler et al. 1992). Further studies, 
however, provided some suggestions of PrP function including copper binding and 
regulation of copper homeostasis (Brown et al. 1998; Kretzschmar 1999), protection 
against oxidative stress (Milhavet et al. 2000), cell signalling (Mouillet-Richard et al. 
2000) and cell adhesion (Gauczynski et al. 2001). In addition, PrP N-linked 
glycosylation is highly conserved, indicating important roles these glycans might play 
in PrP function or prion disease pathogenesis. However, it remains unclear what these 
roles might be. 
1.4 GLYCOSYLATION 
Glycosylation is the process of adding sugar chains to proteins or lipids, giving rise to 
glycoproteins and glycolipids respectively. Apweiler and colleagues (1999) estimated 
that more than half of all eukaryotic proteins contain covalently linked sugar chains. 
Unlike their protein counterparts, the carbohydrate chains of glycoproteins are 
enzymatically generated and covalently linked to the polypeptide without the rigid 
guidance of nucleic acid templates. For this reason, glycoproteins exhibit 
heterogeneity in terms of its protein surface carbohydrate composition. Protein 
glycosylation falls into two groups: N-linked oligosaccharides and O-linked 
oligosaccharides. N-linked glycans are sugar chains covalently linked to an asparagine 
(N) residue of a polypeptide chain within the consensus peptide sequence Asn-X-
Ser/Thr. On the other hand, O-linked glycans are attached to the polypeptide via N-
acetylgalactosamine (GalNAc) to a serine or threonine residue. For the purpose of this 
study, only N-linked glycosylation will be discussed since PrP carries only N-linked 
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glycans. Although PrP posseses potential O-linked glycosylation sites, no O-glycans 
have been identified to date (Bennett et al. 1999). 
1.4.1 N-glycan processing 
N-linked glycosylation begins with the formation of a dolichol oligosaccharide 
precursor composed of 14 specific monosaccharides attached to a lipid carrier 
molecule called dolichol (Figure 5). This 14-mer sugar chain contains 3 glucose 
residues, 9 mannose residues and 2 N-acetylglucosamine (GlcNAc) residues which 
are then transferred en bloc to the amide nitrogen of an Asparagine (Asn) residue in 
the sequence Asn-X-Ser/Thr (Kornfeld and Kornfeld 1985). Further processing of the 
oligosaccharide chain occurs via the concerted actions of glycosidases and 
glycosyltransferases as the glycoprotein is trafficked through the endoplasmic 
reticulum (ER) and Golgi apparatus. In some glycoproteins, brief processing results in 
“high mannose” type oligosaccharides. More extensive processing can give rise to 
glycoproteins with a plethora of sugar groups classified as “hybrid”- or “complex”-
type oligosaccharides. High mannose glycans are those that terminate in unsubstituted 
mannose residues while hybrid glycans are defined as those with both substituted (N-
acetylglucosamine (GlcNAc) linkage) and unsubstituted mannose residues. On the 
other hand, complex glycans refer to those in which both the α-3- and α-6 linked 




Figure 5: N-linked glycan biosynthesis pathway 
During N-linked glycan biosynthesis, monosaccharides of GlcNAc (N-
acetylglucosamine) and mannose are activated or interconverted and used to build the 
lipid-linked oligosaccharide precursor (LLO), which is assembled on dolichol, a 
polyisoprenoid that is derived from the cholesterol pathway. Dolichol in the 
enoplasmic reticulum (ER) membrane is activated to dolichol phosphate by a kinase. 
UDP-GlcNAc provides GlcNAc-1-phosphate and GlcNAc, and GDP-mannose 
provides five mannose residues that are added on the cytoplasmic side of the ER. The 
resulting mannose5-GlcNAc2-P-P-dolichol flips into the ER lumen, where 4 mannose 
and 3 glucose residues are added using dolichol-P-mannose and dolichol-P-glucose 
donors, respectively. An oligosaccharyltransferase complex delivers the glycan to 
asparagine residues in the nascent protein core. The protein-bound glycan is trimmed 
to mannose8-GlcNAc2-protein in the ER and is trimmed further in the Golgi. One 
GlcNAc residue is added to the trimmed mannose5 structure, and this GlcNAc can be 
extended with galactose and sialic acid to form a hybrid glycan or, by adding more 
GlcNAc, branching can continue to form complex-type oligosaccharides. Nucleotide 







N-glycan biosynthesis has been well characterized and extensively reviewed 
(Kornfeld and Kornfeld 1985; Schachter 2000; Trombetta 2003; Freeze 2006). It takes 
place under the concerted actions of glycosidases and glycosyltransferases. These 
enzymes are grouped into families based on the type of sugar they cleave away or 
transfer. Glycosidases include glucosidases and mannosidases which hydrolyze 
specific glycan linkages resulting in the trimming of the specific monosaccharides, 
glucose and mannose residues respectively in this case, from the oligosaccharide 
chain. Most of the enzymes involved in glycan biosynthesis, however, are 
glycosyltransferases. These enzymes extend the oligosaccharide chain by transferring 
the monosaccharide component of high-energy nucleotide sugar donors, such as 
GDP-Mannose and UDP-glucose, to acceptors including saccharides and dolichol-
phosphate (see reaction below). Dolichol-phosphate is involved in the initial steps of 
N-glycan biosynthesis (Figure 5).  
 
N-glycan biosynthesis occurs mostly in the lumen of the Golgi apparatus, where the 
catalytic sites of glycosyltransferases reside (Paulson and Colley 1989). However, the 
sugar nucleotides are made in the cytosol and must be transported into the Golgi 
lumen for glycosylation to occur. Thus the action of each glycosyltransferase can be 
regulated at several levels including the intra-luminal concentration of the sugar 
nucleotide donor and acceptors, and the presence of specific sugar nucleotide 
degrading enzymes and glycosidases, the latter of which alters the acceptor molecule 
available for binding glycosyltransferases. In addition, two glycosyltransferases often 
have the same substrate specificity but different acceptor recognition, or that they may 
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recognise different substrates but act on the same acceptor molecules. 
Glycosyltransferases of the latter type can be mutually exclusive in the assembly line 
of glycan formation because whichever enzyme modifies the substrate first can 
thereby redirect the synthetic pathway and alter the structural outcome. This was 
observed in the in vitro enhancement of N-acetylglucosaminyltransferase-V (GnT-V)-
induced cell migration due to knockdown of GnT-III expression in CHP134 cells, a 
human neuroblastoma cell line (Zhao et al. 2006). Although both GnT-III and GnT-V 
act on the same acceptor substrate (see reaction below), when the former adds a 
bisecting GlcNAc residue in β1-4 linkage to the conserved pentasaccharide core, it 
inhibits further branching by GnT-V (Figure 6). 
 
 
Figure 6: Schematic representation of GnT-III and GnT-V catalytic activity 
The catalytic activity of GnT-III and GnT-V is mutually exclusive because 
competition by GnT-III for the same substrate would inhibit the action of GnT-V. 
 
Such competition by other glycosyltransferases for the same donor or acceptor is 
another way to regulate the action of glycosyltransferases, thereby contributing to the 
structural diversity of the glycan chains. In intact cells, most, if not all, of these 
factors may interact to determine the final structures of the glycans synthesized on a 
given glycoprotein that passes through the secretory pathway.  
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1.4.3 Structural diversity 
There are 4 sources of glycan diversity. [1] Glycosylation is not template driven. The 
final oligosaccharide formed on a polypeptide or lipid molecule is dependent upon the 
timely availability (albeit ordered sequence) of specific glycosyltransferases, 
glycosidases and their respective substrates. [2] Also unlike nucleic acids and proteins, 
carbohydrates can form branched structures, thereby giving them the potential to carry 
more biological information. [3] Adding to the complexity of glycan structures 
formed is the fact that the glycosidic bonds formed between two monosaccharides can 
take one of two anomeric configurations. [4] Upon complete glycosylation, the 
oligosaccharide chains may be further modified by processes such as acetylation and 
sulfation (Klein and Roussel 1998; Fukuda et al. 2001). With these four sources of 
glycan diversity, one can imagine the myriad of sugar chains that can form on 
identical proteins in glycoprotein synthesis, making glycan analysis a technical 
challenge.  
1.4.4 Functional consequence 
Glycan do not simply decorate glycoconjugates. Tunicamycin inhibition of N-linked 
glycosylation showed that N-glycans ensure the proper folding of nascent 
polypeptides in the ER (Kornfeld and Kornfeld 1985; Olden et al. 1982; Hurtley and 
Helenius 1989; Klausner and Sitia 1990) and play a role in intracellular protein 
trafficking. Genetic deficiency in N-acetylglucosamine-1-phosphotransferase results 
in loss of the carbohydrate side chain containing mannose-6-phosphate in lysosomal 
enzymes. This leads to disrupted lysosomal trafficking and the development of a 
severe inherited lysosomal storage disorder called I-cell disease, characterized by 
retarded physical and mental development (Leroy et al. 1969; Waheed et al. 1982).  
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Given the conformational mobility of carbohydrate chains, oligosaccharides attached 
to proteins can occupy large spatial volumes, shielding a protein’s surface and 
possibly offer protection against proteolysis or sterically modifying its activity. In 
addition, exposure of glycans on the cell surface makes them excellent candidates as 
mediators of cell-cell interaction due to their ability to bind to glycan-binding proteins 
(Rudd et al. 2004).  
 
N-glycans are often capped with sialic acid residues which comprise a family of >50 
structural variants with nine-carbon backbone monosaccharide (Schauer 2000; Angata 
and Varki 2002). These sialic acids are expressed in a cell-type and developmentally 
regulated manner (Rutishauser and Landmesser1996; Varki 2007). Inactivation of 
UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase, a key enzyme 
involved in initiating sialic acid biosynthesis, caused early embryonic lethality in mice 
(Schwarzkopf et al. 2007). In addition, reduced content of polysialic acids on neural 
cell adhesion molecule (NCAM) with development was reported (Edelman and 
Chuong 1982; Rutishauser and Landmesser 1996). Although the causal role of 
polysialic acid reduction is unknown, it may be related to the expression of polysialic 
acid mainly in brain tissues that exhibit continued physiological plasticity in adult life 
such as the olfactory system and dentate gyrus. Failure of “staggerer” mice to produce 
adult forms of NCAM with reduced surface sialic acids as compared to the embryonic 
forms resulted in severe connection defects in the cerebellar regions of these mutant 
mice (Edelman and Chuong 1982). These polyanionic sialic acids are believed to play 
a role in maintaining developmental plasticity by regulating homo- and hetero-typic 
interactions between neuronal cells (Rutishauser and Landmesser 1996; Bruses and 
Rutishauser 2001) which are important for proper axonal trafficking (Miller et al. 
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1994), emotional and cognitive memory (Cremer et al. 1994), and brain 
morphogenesis (Bonfanti et al. 1992) to occur. For instance, in the rat dentate gyrus 
denervated by ipsilateral entorhinal cortex lesion, embryonic NCAM is elevated and 
accompanied by extensive synaptic degeneration, axonal sprouting and 
synaptogenesis (Miller et al. 1994). In addition, NCAM-deficient mice showed 
impaired spatial learning when tested in the Morris water maze (Cremer et al. 1994). 
Taken together, these results suggest that sialic acids play a critical functional role in 
the development of the nervous system. 
1.5 ROLE OF GLYCOSYLATION IN AGEING 
The term “glycogerontology” was introduced to describe the study of the structure, 
biosynthesis and biology of saccharides (termed “glycobiology”) in the field of ageing 
research (Kobata 2003). It is increasingly recognised that there is a strong association 
between ageing and specific glycosylation changes occurring within the organism. It 
was reported that the galactose content of human serum IgG decreased with age 
(Parekh et al. 1988; Tsuchiya et al. 1993). Similar deficiency was observed in serum 
IgG from patients with rheumatoid arthritis (RA), an inflammatory condition of the 
joints frequently observed in aged individuals (Parekh et al. 1985). This hypo-
galactosylation, due to reduced B cell galactosyltransferase activity (Furukawa et al. 
1990; Axford et al. 1987), resulted in decreased IgG binding to C1q and human Fcγ 
receptor type I (Tsuchiya et al. 1989) and increased binding of the exposed underlying 
GlcNAc to mannose binding protein (Malhotra et al. 1995). The consequent aberrant 
complement activation contributes to the chronic inflammation of the synovial 
membrane in the ageing rheumatoid joint.  
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Besides its involvement in immunodeficiency in aged individuals, glycosylation 
changes also play a role in neuronal ageing. It is estimated that at least 30% of the 
proteins expressed in the human brain are glycosylated (Kanninen et al. 2004). This 
figure is likely to be an underestimate given the fact that enrichment of less abundant 
glycosylated proteins in specialized compartments such as the synaptosomes and 
nuclei make it hard for the existing techniques to sensitively detect them. In a 
comparative study, the N-linked sugar composition of glycoproteins in the brain 
during ageing was analysed using western blotting with biotinylated-lectins targeted 
towards specific glycans structures (Sato et al. 1998). Results showed that the glycan 
profile on neuronal proteins differs between various brain regions as well as between 
young adult and aged rats. For example, glycoproteins with molecular weights of 133 
and 125 kDa, detected by staining with Lens culinaris agglutinin (LCA) in the 
membrane fractions of white matter and basal ganglia, decreased in the aged rats. On 
the other hand, another LCA-positive 30 kDa glycoprotein in the membrane fraction 
of the spinal cords was detected only in aged but not in young adult rats. In addition, 
this protein was progressively glycosylated in the spinal cord during the ageing 
process (Sato et al. 1999b). This protein was later confirmed to be the major structural 
component of mammalian peripheral nervous myelin termed the P0 protein (Sato et al. 
1999b; Lemke and Axel 1985; Giese et al. 1992), whose glycosylation is involved in 
homophilic cell-cell adhesion required for maintenance of compact myelin (Yazaki et 
al. 1992; Filbin and Tennekoon 1993). Although the age-related mechanism and 
biological significance of glycosylated P0 in aged rat spinal cord and aglycosylated P0 
in young adult rat spinal cord remains to be elucidated, these glycosylation 
differences lend strong support for a critical role that glycosylation plays during 
ageing in the peripheral nervous system. 
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Further support for a functional significance of glycosylation changes during ageing 
in the nervous system was provided by the differential expression of 
sialoglycoproteins in the ageing rat hippocampus. The expression levels of α2-3 and 
α2-6 sialoglycoproteins were shown to be down-regulated in the aged rat 
hippocampus (Sato and Endo 1999a; Sato et al. 2001) where they may modulate 
cerebellar associated navigational brain functions (Petrosini et al. 1996) through 
intercellular interaction with a sialic acid-binding molecule such as the siglec family 
of proteins (Varki and Angata 2006). 
 
Age-associated glycosylation changes were also reported in the rat cerebellum (Sasaki 
et al. 2002; Keino et al. 1998) and hamster liver (Krześlak and Lipińska 1996). The 
association of ageing and glycosylation changes can be explained by the non-template 
driven nature of glycan biosynthesis. This lack of definitive regulation on glycan 
biosynthesis accounts for the high susceptibility of these secondary gene products to 
changes induced by altered physiological conditions of the cells (Lowe 2001) such as 
in the instance of organism-wide deterioration brought on by ageing. Understanding 
the biological mechanisms of age-related glycosylation changes may provide useful 
information about the functional roles of glycans and facilitate the development of 
geriatric medicine. 
1.6 ROLE OF GLYCOSYLATION IN NEURODEGENERATION 
Several neurological disorders have been reported to exhibit characteristic changes in 
the glycosylation pattern of proteins. These glycosylation changes may be attributed 
to alterations in the contribution by different protein glycoforms (Sáez-Valero et al. 
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1999), differences in the cellular origin of the glycoprotein (Botella-López  et al. 2006) 
or altered glycosylation mechanism (van Rensburg et al. 2004; Wang et al. 1996).  
 
Interestingly, congenital disorders of glycosylation (CDGs) are often associated with 
mental impairments of varying degrees (Freeze 2006). CDGs are autosomal recessive 
defects in N-glycosylation biosynthesis attributed to either insufficient and/or 
incomplete synthesis of the 14-sugar dolichol-phosphate-linked oligosaccharide 
(Freeze 2001; Jaeken et al. 2001; Marquardt et al. 2003), or altered processing of the 
protein-bound glycans (Freeze 2006). Although mental retardation differs from 
neurodegeneration in that the former is often used to describe the incomplete or 
arrested development of the mind while the latter refers to the “catabolic” effect of 
neuronal cell loss, the pathological features of CDGs further corroborates the 
involvement of glycosylation in the proper functioning of the brain (Turner 1996; 
Przedborski et al. 2003).  
 
Given the large proportion of glycosylated brain proteins (Kanninen et al. 2004) as 
well as the myriad of neurological diseases associated with aberrant glycosylation, the 
role of glycosylation in brain function is undeniable. Studies by Yang and Charlwood 
and their colleagues further support this notion. Both studies showed that 
glycosylation regulates the functions of proteins and may in turn play a role in 
neurodegenerative disorders such as Alzheimer’s disease (Yang et al. 2002; 
Charlwood et al. 2001). Yang and colleagues showed that the assembly of the active 
γ-secretase multienzymatic complex is compromised when a component protein, 
nicastrin, is aberrantly glycosylated (Yang et al. 2002). At the same time, BACE-1 
enzymatic activity was reduced as a result of deviant glycosylation (Charlwood et al. 
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2001). Both these proteins are involved in cleavage of amyloid precursor protein, a 
process which when wrongly executed can give rise to the production of Aβ (1-42) 
fragment that is responsible for Alzheimer’s disease. Taken together, these results 
highlight an important role of aberrant glycosylation in neurodegenerative diseases 
and understanding the underlying mechanism is of great scientific importance.  
1.7 ROLE OF GLYCOSYLATION IN PRION DISEASE 
PrP is a sialoglycoprotein ubiquitiously expressed in all mammals studied to date 
(Stahl et al. 1987). It is expressed in nearly all tissues and is particularly abundant in 
neurons (Kretzschmar et al. 1986a), which constitute the major targets of TSE-related 
degeneration. As discussed, the physiological condition of cells can modulate the 
glycans attached to glycoproteins. Hence, alteration of the sugar chains of PrP is an 
important target in prion research.  
 
The roles that N-linked glycans play in the functions of PrPC are not completely 
understood. However, the fact that both N-glycosylation sites are highly conserved in 
the PrP gene from all species suggests an important role for these N-glycans in the 
protein function (van Rheede et al. 2003). Given the physical characteristics and 
particularly their high hydropathy, these saccharides usually interact with the 
environment and may contribute to the function of membrane-bound PrPC by 
mediating interaction processes such as cell-cell signalling.  
 
Several reports using in vitro models have showed that the lack of these N-glycans 
favours the PrPC to PrPSc transition. These studies performed either by tunicamycin 
inhibition of N-linked glycosylation or by site-directed mutagenesis of one or both the 
glycosylation sites, suggest that perturbations in PrP glycosylation may contribute to 
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prion disease development by destabilizing the PrP structure, hence enhancing its 
propensity of acquiring PrPSc-like properties (Taraboulos et al. 1990; Lehmann and 
Harris 1997; Neuendorf et al. 2004). Accordingly, PrPSc was reported to have a lower 
content of glycans at both its N-glycosylation sites than PrPC (Somerville et al. 2005). 
 
Characterization of the N-glycans using high-performance liquid chromatography 
(HPLC) and electrospray mass spectrometry demonstrated that PrPC and its 
pathological conformer (PrPSc) present differential glycosylation patterns in CJD 
(Endo et al. 1989; Stimson et al. 1999; Rudd et al. 1999). In particular, Rudd and 
colleagues showed that the proportion of bisecting glycans was reduced while that of 
tri- and tetra-antennary glycans was increased in PrPSc from Syrian hamsters (Rudd et 
al. 1999). In agreement, structural studies showed that PK resistant PrP 27-30 
contains a heterogeneous mixture of bi-, tri- and tetra-antennary complex-type 
glycans, possibly yielding over 400 variants of the PrPSc (Endo et al. 1989). Site-
specific characterization of murine PrPSc revealed Asn-180 to carry mainly LewisX 
trisaccharide while Asn-196 carries significant amounts of both LewisX and sialyl 




Figure 7: Glycosylation difference between PrPC and PrPSc as determined by 
positive ion delayed extraction MALDI MS 
The percentage change in relative glycan abundance in the PrPSc spectrum compared 
with that in PrPC is shown as a difference spectrum. Results show that the levels of 
tri- and tetra-antennary sugars are elevated in PrPSc (upper trace) while that of bi-
antennary sugars are reduced in PrPSc compared to PrPC (lower trace). (Adapted from 
Rudd et al. 1999) 
 
Interestingly, altered protein glycosylation in CJD does not appear to be restricted to 
PrP. Other proteins such as the insulin receptor and acetylcholinesterase also exhibit 
perturbed glycosylation in scrapie-infected neurolastoma cells (Nielsen et al. 2004), 
and in the cerebrospinal fluid and brain of CJD individuals (Silveyra et al. 2006), 
respectively. These observations have led to the proposal that scrapie prion infection 
may perhaps influence glycosylation of other proteins in, at least, some cells in which 
PrPSc is formed (Rudd et al. 1999; Hounsell 2004). However, the significance of 





To date, the molecular events underlying the pathogenic transition from PrPC to PrPSc 
remains an enigma. Many studies suggest that carbohydrate biopolymers displayed on 
the protein surface may facilitate the pathogenic conversion process by destabilizing 
PrPC structure. In depth analysis of the glycan profile on normal hamster PrPC and 
scrapie-infected hamster PrPSc was achieved by Rudd and colleagues (1999) using 
HPLC and mass spectrometry techniques. However, prion disease mostly manifests as 
an age-related neurodegenerative disorder. Yet analysis of the glycan profile of PrPC 
during the ageing process has not been examined. This is noteworthy because just as 
aberrant glycosylation has been found to be associated with prion disease, specific 
changes in glycan profiles are known to correlate with certain disease states such as 
cancer (Hutchinson et al. 1991; Miyoshi et al. 1999; Ishimura et al. 2006; Peracaula 
et al. 2003) and inflammation (Raghav et al. 2006; Higai et al. 2003; Parekh et al. 
1985). This suggests the use of glycan profiling in clinical diagnosis and possibly as 
therapeutic targets. In this study, the glycan profile of PrPC during neuronal ageing is 
analysed and any correlations with the glycan profiles already described for PrPSc will 
be discussed. This would undoubtedly provide further insight into the functional 
significance of these PrP-bound glycans and the hitherto enigmatic molecular 






















2. MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 Animals 
The experimental protocols involving laboratory mice were carried out in accordance 
with guidelines approved by the Institutional Animal Care and Use Committees 
(IACUC) at the National University of Singapore and University of Melbourne. 
 
C57BL/6J mice were sacrificed 2, 4, 8, 16, 32 and 64 weeks post-natal. The 
B6.129SV mice brain samples used in this study were kindly provided by Dr Roberto 
Cappai and Dr Joe Ciccotosto of University of Melbourne. B6.129SV mice were 
sacrificed 2, 4, 8, 18, 52 and 82 weeks post-natal. At least 3 brains (n ≤ 3) from each 
age group were used in all analysis. Brains from prion protein knockout (Prnp-/-) mice 
used in this study were obtained as originally described by Bueler et al. (1992).  
2.1.2 Antibodies  
The anti-PrP monoclonal antibodies (MAb) used in this study were kindly provided 
by Professor Man-Sun Sy of Case Western Reserve University, USA. The methods in 
the generation and characterisation of these anti-PrP antibodies has been described 
previously (Zanusso et al. 1998; Li et al. 2000). The MAb 8B4, MAb 8H4 and MAb 
8F9 used in this study are of the immunoglobulin G1 (IgG1) subclass, and the epitopes 
recognized by these MAbs are diagrammatically presented in Figure 1. Biotinylation 
of anti-PrP MAbs was performed using the EZ-linked™ Sulfo-NHS-Biotin kit (Pierce, 
Rockford, IL, USA). 
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Rabbit anti-actin polyclonal antibody was purchased from Sigma (St Louis, MO, 
USA).  
2.1.3 Chemicals and Enzymes 
Tri-Glycine-SDS running buffer (10x) and LB Broth were purchased from 1st Base 
Pte Ltd (Singapore). MOPS buffer (10x) was purchased from Ambion (Austin, TX, 
USA). Carbenicillin and Imidazole were purchased from AppliChem (Cheshire, CT, 
USA). Glycerol and Luria-Broth-Agar (Miller) were purchased from Asia Pacific 
Specialty Chemicals (San Diego, CA, USA) and BD Difco (Franklin Lakes, NJ, USA) 
respectively. 
 
Ammonium Persulphate, 30% Acrylamide/Bis Solution (37.5:1), N,N,N',N'-
Tetramethylethylenediamine (TEMED), 0.5M Tris (pH 6.8) and 1.5M Tris (pH 8.9) 
were purchased from Bio-Rad Laboratories (Hercules, CA, USA). Restore Western 
Blot Stripping buffer, S.O.C media, Tris-Glycine transfer buffer (25x) and TRIzol 
were purchased from Invitrogen (Carlsbad, CA, USA). 
 
Agarose and Absolute alcohol (A. R. Quality) were purchased from Cambrex Bio 
Science (Hopkinton, Massachusetts, USA) and Hayman Limited (Witham, Essex, 
England) respectively. Isopropyl-β-D-thiogalactopyranoside (IPTG) and RNA loading 
dye (2x) were purchased from MBI Fermentas (Burlington, Ontario, Canada). 37% 
Formaldehyde and Isopropanol were purchased from J. T. Baker (Phillipsburg, NJ, 
USA) and Kanto Kagaku Singapore (Singapore) respectively. 
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Phosphate Buffered Saline (10x), NaCl and 10% sodium dodecyl sulphate (SDS) were 
purchased from a local supply store, National University Medical Institutes (NUMI, 
Singapore). 
 
Reverse transcription buffer (5x), Recombinant RNasin® Ribonuclease Inhibitor, 
Oligo(dT) 15 Primer, AMV Reverse Transcriptase and 10mM dNTP mix were 
purchased from Promega (Madison, WI, USA). 2,2-azino-di-(3-ethylbenzthiazoline 
sulfonic acid) ammonium salt solution (ABTS) and Nonidet P-40 were purchased 
from Roche Diagnostic (Indianapolis, IN, USA). 
 
Bromophenol blue, β-mercaptoethanol, Bovine serum albumin (BSA), diethyl 
pyrocarbonate (DEPC), proteinase K (PK) and urea were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Tris (Base) and chloroform were purchased from Tee 
Hai Chem (Singapore) and Merck Ltd (Frankfurt, Germany) respectively.  
 
Peptide N-glycosidase F (PNGase F) and Neuraminidase were purchased from New 
England BioLabs (Ipswich, MA, USA).  
2.2 METHODS 
2.2.1 Preparation of Brain Homogenates 
Brain homogenates (20% w/v) were prepared by homogenizing the frozen mice brain 
tissues in lysis buffer containing phosphate-buffered saline (PBS), 0.5% Nonidet P-40, 
0.5% sodium deoxycholate, supplemented with a Complete™ protease inhibitor 
cocktail (Roche Diagnostic, Indianapolis, IN, USA). Homogenization was performed 
on ice for 3 cycles of 30sec each, with a 30 seconds pause in between to prevent 
protein degradation due to the heat generated by the Power Gen 500 homogenizer 
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(Fisher Scientific, UK). The protein concentrations were determined (Bradford 
method) and the crude homogenates were stored in aliquots at -80ºC. 
2.2.2 Bradford Protein Quantification 
The concentration of proteins was quantified spectrophotometrically (SpectraMax 190, 
Molecular Devices, USA) at 595nm using the Coomasie Plus™ – Bradford Assay Kit 
(Pierce, Rockford, IL, USA). A calibration curve was constructed using bovine serum 
albumin, provided in the kit, at a range of 0µg/ml - 25µg/ml.  
2.2.3 Protease Digestion 
Proteinase K (PK) digestion was performed by incubating 40µg total brain 
homogenate proteins with 0, 0.2, 5, 25 and 50µg/ml of PK (Sigma, St Louis, MO, 
USA) for 1hr at 37°C. The proteolytic reaction was terminated by heat denaturation of 
the mixture at 95°C for 10min in 4x gel loading buffer (40% Glycerol, 4% SDS, 
0.25M Tris pH 6.8, 0.05% Bromophenol Blue), followed by electrophoretic 
separation on Tris-Glycine gels. 
2.2.4 Western Blot Analysis 
Forty micrograms of total protein were separated by SDS-PAGE (12% acrylamide) 
and transferred onto a nitrocellulose membrane (Trans-Blot® Transfer Medium 
(0.45µm), BioRad, CA, USA). After transfer, the unbound sites were blocked with 
5% non-fat milk in PBST (PBS and 0.1% Tween-20) for 1hr. The membrane was then 
probed with the respective primary antibodies for 1hr and exposed to horseradish 
peroxidase (HRP)-conjugated secondary antibodies for 45min. The respective protein 
bands were then visualized by chemiluminescence using the SuperSignal® West Dura 
Extended Duration Substrate (Pierce, Rockford, IL, USA) system on an SR-2000 
chemiluminescence image station (Kodak, USA). Pre-stained protein standards (Bio-
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Rad Laboratories, Hercules, CA, USA) were used to calculate the apparent molecular 
weight of the protein bands. The optical density of the reactive PrP bands, relative to 
the endogenous β-actin level, was quantified using Kodak Digital Science ID 
Software. 
2.2.5 Glycoenzymatic Treatment 
For peptide N-glycosidase F (PNGase F) treatment (Pan et al. 2002a), 40µg of total 
brain protein were mixed with 0.1 volume of 10x denaturing buffer (0.5% SDS, 1% β-
mercaptoethanol) and heated for 10min at 95ºC. Seven hundred and fifty units of 
PNGase F (New England BioLabs, Ipswich, MA, USA) was then added into the 
denatured protein mixture, and incubated at 37ºC for 1.5hr in 5mM sodium phosphate 
and 1% Nonidet P-40. The endoglycolytic cleavage was terminated by heat-
inactivation of the enzyme at 95ºC for 10min. 
 
For neuraminidase (New England BioLabs, Ipswich, MA, USA) digestion (Pan et al. 
2002a), 40µg of total brain protein were incubated overnight at 37ºC in 50mM sodium 
citrate containing 75units of neruaminidase. The exoglycolytic cleavage was 
terminated by heat-inactivation of the enzyme at 95ºC for 10min. 
 
For combined PNGase F and neuraminidase digestion, 40µg of total brain protein 
were mixed with 0.1 volume of 10x denaturing buffer (0.5% SDS, 1% β-
mercaptoethanol) and heated for 10min at 95ºC. The mixture was incubated with 
750units of PNGase F and 75units of neuraminidase at 37ºC for 4hr in 5mM sodium 
phosphate and 1% Nonidet P-40. The enzymatic cleavage was terminated by heat-
inactivation of the enzyme at 95ºC for 10min. 
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2.2.6 Immunoprecipitation 
Immunoprecipitation of full length PrP from total brain homogenates was carried out 
as described by Pan et al. (2002a) with slight modifications. Five hundred µg of total 
brain homogenate was equilibrated with 5µg of MAb 8B4 at 4ºC overnight. Protein G 
agarose beads (Roche Diagnostic, Indianapolis, IN, USA) were then allowed to 
couple to the MAb for 3hr at 4ºC. Full length PrP from total brain homogenates were 
removed by pelleting the beads via centrifugation at 12,000g for 20 seconds, leaving 
truncated PrP in the brain homogenates remaining in the supernatant fraction. The 
efficiency of the immunodepletion process was examined by immunoblotting.  
2.2.7 Expression and Purification of Recombinant Prion Protein 
The expression of recombinant mouse prion protein, encoding residues 23 to 231 of 
wild-type mouse Prnp gene was carried out as previously reported (Wong et al. 2000). 
The amplified product was cloned into the expression vector, pEXP1-DEST 
(Invitrogen, CA, USA) and transformed into Origami™ (DE3) competent cells 
(Novagen, Darmstadt, Germany) for expression of PrP protein. The genotype of 
Origami™ (DE3) competent cells is ∆(ara-leu)7697 ∆lacX74 ∆phoA PvuII phoR 
araD139 ahpC galE galK rpsL F’[lac+ lacI pro] (DE3) gor522::Tn10 trxB (KanR, StrR, 
TetR). These cells possess mutations in both thioredoxin reductase (trxB) and 
glutathione reductase (gor) genes, thereby allowing proper PrP disulphide bond 
formation in the C-terminal region. pEXP1-DEST expression vector carries a 
polyhistidine tag (6xHis) at the N-terminal region thus allowing for purification of the 
recombinant protein by binding to a nickel-based column.  
 
The bacterial cell culture was grown at 37°C to an OD600 of 0.5, after which protein 
synthesis was induced by the addition of 1mM isopropyl-β-D-thiogalactopyranoside 
 33 
(IPTG). The bacteria were harvested after 2hr and recombinant protein was extracted 
using the BugBuster® Protein Extraction Reagent*1 (Novagen, Darmstadt, Germany) 
according to the manufacturer’s specifications. Briefly, cells were harvested by 
centrifugation at 5000g for 5min at 4°C and resuspended in1x BugBuster® reagent 
containing 25U Benzonase® Nuclease and 1kU recombinant Lysozyme (rLysozyme) 
per ml BugBuster reagent. Benzonase® Nuclease (Novagen, Darmstadt, Germany) 
was added to reduce the viscosity of the extract due to the liberation of chromosomal 
DNA. The addition of rLysozyme (Novagen, Darmstadt, Germany) enhances 
extraction efficiency by hydrolyzing N-acetylmuramide linkages in the bacterial cell 
walls. Following a brief incubation, insoluble cell debris is removed by centrifugation. 
After 5 successive rounds of extraction and centrifugation, recombinant PrP protein 
was extracted from the highly purified inclusion bodies by resuspending in Buffer A 
(PBS containing 8M urea, 200mM Sodium chloride and 20mM Tris-HCl, pH8.0). 
 
The suspension was applied onto a Nickel-Nitrilotriacetic acid (Ni-NTA) resin 
(Invitrogen, Carlsbad, CA, USA) column for purification of the 6xHis-Tagged 
recombinant protein. The column was washed twice with Buffer A and subsequently 
twice with Buffer A containing 5mM imidazole. The protein was eluted using 300mM 
imidazole in Buffer A. Refolding of prion protein was carried out by several 
successive rounds of dilution in PBS and protein concentration using Amicon Ultra-
15 Centrifugal Filter units (10,000 MWCO) (Millipore, Billerica, MA, USA). The 
efficiency of the purification process was assessed by immunoblotting with anti-PrP 
MAb 8H4.  
                                               
* Exact composition of buffer is not provided by the manufacturer. 
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2.2.8 Quantification of Brain-Derived Prion Protein 
The quantity of PrP in total brain homogenates was analyzed alongside known 
quantities of recombinant mouse PrP (rec-moPrP) using sandwich ELISA as 
previously described (Wong et al. 2003). MAb 8F9-immunocaptured rec-moPrP was 
detected with biotinylated MAb 8H4 and a linear standard graph of OD405 against rec-
moPrP concentration was plotted. This standard was used to determine the amount of 
PrP in each brain homogenate.  
2.2.9 Lectin ELISA 
An ELISA plate (96-well; Nunc, Naperville, IL, USA) was coated with 100ng of 
affinity purified either MAb 8B4 or 8F9 overnight at 4°C (Pan et al. 2005a) before 
washing three times with PBST (PBS + 0.1% Tween-20). Unbound site were blocked 
with 3% bovine serum albumin (BSA) in PBS and subsequently washed three times 
with PBST. 500µg of total brain homogenates were added to the MAb 8B4-coated 
wells, and MAb 8B4-immunodepleted brain homogenates containing truncated PrP 
species were added to the MAb 8F9-coated wells, before incubating them overnight at 
4°C. The plate was washed three times with PBST before incubation with a variety of 
biotinylated lectins (Vector Laboratories, Burlingame, CA, USA) for 1hr at room 
temperature. The carbohydrate specificity of the panel of lectins is given in Table 1. 
Bound lectins were detected with HRP-conjugated streptavidin (BD Pharmingen, San 
Jose, CA, USA) incubated at room temperature for 1hr after washing the plate thrice 
with PBST. Unbound secondary antibodies were removed by washing three times 
with PBST. Immunoreactivity was determined by examining the optical density 
values at 405nm. The absorbance was measured with 2,2-azino-di-(3-
ethylbenzthiazoline sulfonic acid) ammonium salt solution (ABTS) (Roche 
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Diagnostic, Indianapolis, IN, USA). The results presented are the average of 
duplicates for individual sample.  
2.2.10 Total RNA Extraction (Using TRIzol Reagent) 
Frozen mice brains were weighed prior to total RNA extraction.  One ml of TRIzol 
reagent (Invitrogen, Carlsbad, CA, USA) was used for extracting 50-100mg of tissue. 
The brain samples were homogenized on ice for 3 cycles of 30 sec each, with a 30 
seconds pause in between to prevent nucleic acid degradation due to the heat 
generated by the Power Gen 500 homogenizer (Fisher Scientific, UK). Each 
homogenate was incubated at room temperature for 5min following which 200µl of 
chloroform was added per ml of TRIzol used for extraction. The mixture was then 
vortexed vigorously for 15sec and allowed to incubate for 3min at room temperature. 
Centrifugation at 13,000rpm for 15min at 4°C was then performed to allow phase 
separation. The top aqueous phase was carefully transferred into a fresh tube and 
incubated with 500µl of isopropanol per ml TRIzol used, to precipitate the RNA. The 
mixture was incubated at room temperature for 10min and subsequently subjected to 
centrifugation at 13,000rpm for 10min at 4°C. The supernatant was later discarded 
and 1ml of ice-cold 75% ethanol (in 0.1% diethylpyrocarbonate (DEPC)-treated water) 
was used to wash the pellet by vortexing and centrifuging at 9,000rpm for 5min at 
4°C. Upon removal of the ethanol, the RNA pellet was air-dried prior to re-dissolving 
in 50µl of 0.1% DEPC-treated water.  
 
Contaminating DNA was digested using 3U of RQ1 (RNA-qualified) RNase-Free 
DNase (Promega, Madison, WI, USA) per 10µl of RNA at 37 C for 20min. Further ˚
purification of the RNA obtained was performed using the Rneasy Mini Kit (Qiagen, 
Valencia, CA, USA). Briefly, 350μl of Buffer RLT* (containing 10μl β-
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mecaptoethanol per ml of Buffer RLT) was added and the mixture was centrifuged at 
14,000g for 3min. The supernatant was transferred to a fresh tube and 350µl of 70% 
ethanol was used to precipitate the RNA. This mixture was transferred to an RNeasy 
spin column and centrifuged at 14,000g for 15 seconds. The RNeasy spin column 
contains a silica-gel-based membrane to adsorb total RNA. The flow-through was 
discarded and 700µl of Buffer RW1* was added to the spin column. Centrifugation 
was subsequently carried out at 14,000g for 15 seconds and the flow-through 
discarded. 500µl of washing Buffer RPE*2 was added and the mixture was 
centrifuged at 14,000g for 15 seconds. This step was repeated but with centrifugation 
carried out for 2min. After dry-spinning the column for 1min at 14,000g, 15µl of 
RNase-free water was added. The RNA was eluted by centrifugation at 14,000g for 
1min.  
2.2.11 RNA Quantitation 
Each RNA sample was quantified by measuring the absorbance at 260nm using the 
NanoDrop® ND-1000 Full Spectrum UV/VIS Spectrophotometer (NanoDrop 
Technologies Inc., Wilmington, DE, USA). One OD260 = 40µg RNA/ml. The RNA 
concentration was calculated as follows [RNA] = OD260 x 40. The ratio of 
OD260/OD280 was also analysed to assess the purity of the RNA sample. A ratio of 
1.8-2.0 was accepted.  
2.2.12 RNA Gel Electrophoresis 
The RNA integrity was analysed by RNA gel electrophoresis. 0.5g of agarose was 
boiled in 43.5ml 0.1% DEPC-treated water and subsequently allowed to cool prior to 
the addition of 5ml 10X MOPS buffer, 0.8ml 37% formaldehyde and 1µl 10mg/ml 
                                               
* Exact composition of buffer is not provided by the manufacturer. 
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ethidium bromide. The gel was cast and allowed to set. Sample preparation was 
carried out by mixing between 0.5-10µg of RNA sample with 2µl 10X MOPS buffer, 
3.5µl 37% formaldehyde, 10µl deionised formamide and RNA loading dye, used in a 
ratio of 2:1 with respect to the volume of RNA sample added. The mixture was then 
heated at 65°C for 10min before separating on the gel ran at 80 volts using 1X MOPS 
as a running buffer.  
2.2.13 Reverse Transcription of mRNA into cDNA 
Four µg of total RNA was incubated at 70 C for 10min and subsequently cooled on ˚
ice prior to cDNA synthesis. Reverse transcription was performed by the addition of 
0.2 volume of 5x Reverse Transcription buffer, 1mM dNTP mix, 1U/µl Recombinant 
RNasin® Ribonuclease Inhibitor, 15U/µg Avian Myeloblastosis Virus (AMV) 
Reverse Transcriptase, 0.5µg Oligo(dT)15 Primer per µg RNA, in a final reaction 
volume of 80µl. All reagents were obtained from Promega, Madison, WI, USA. 
Reverse transcription was carried out at 42 C for 15min. The AMV Reverse ˚
Transcriptase was heat inactivated by incubating the mixture at 95 C for 5min and ˚
subsequently cooled on ice for 5min. The cDNA was stored at -80 C until use. ˚   
2.2.14 Microarray Analysis 
RNA samples from 3 independent biological replicates were submitted to the 
Consortium for Functional Glycomics at Scripps Research Institute, USA for 
microarray analysis. The quality of the samples was checked with an Agilent 
Bioanalyzer (Agilent Technologies, Palo Alto, CA). RNA from each preparation was 
labelled using the MessageAmp II-Biotin Enhanced Single Round aRNA 
Amplification Kit (Perkin-Elmer Inc) and hybridised to the Affymetrix arrays. Arrays 
were hybridised using standard Affymetrix protocol as described by Lockhart and co-
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workers, 1996 (Protocol available at http://affymetrix.com).  The chips were scanned 
using the Affymetrix ScanArray 3000 using default settings and a target intensity of 
250 for scaling.  
 
The RNA samples were labelled and hybridised to the Affymetrix customized Glyco 
version 3 array, which interrogates 1183 mouse probe-IDs relevant to glycosylation. 
A significant feature of the GLYCOv3 Chip design is its use of 21 probe-pairs per 
gene probe set for improved detection ability. Commercially available Affymetrix 
arrays use 8-11 probe pairs per probe set. A complete description and annotation for 
the GLYCOv3 array is available at 
http://www.functionalglycomics.org/static/consortium/resources/resourcecoree.shtml.  
 
The raw expression values were normalised using Robust Multichip Average 
expression summary (http://rmaexpress.bmbolstad.com/). All further processing of the 
data was performed within the Bioconductor project and the R program software (R is 
available as Free Software under the terms of the Free Software Foundation’s GNU 
General Public License). The most variable 494 genes were selected from the data by 
using the interquartile range as a measure of variance in order to eliminate false 
positives. The fold changes and standard errors were estimated by fitting a linear 
model for each gene and empirical Bayes smoothing was applied to the standard 
errors. The linear modelling approach and the empirical Bayes statistics as 
implemented in the limma package in the R software were employed for differential 
expression analysis. Statistics were obtained for transcripts with an unadjusted p-
value level of ≤ 0.05. Another criterion for up- and down-regulation was a two-fold 
change in mean expression level relative to 2 week old samples. 
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2.2.15 Statistical Analysis for Lectin ELISA 
All data are presented as the mean ± standard error of mean (SEM). Mean values were 
calculated from at least 3 or more individual samples. Where significant testing was 
performed, the R program software (R version 2.3.1) was used to apply One-Way 
ANOVA followed by Tukey’s Honestly Significant Difference (HSD) post hoc test. A 
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3. PRION PROTEIN IN NEURONAL AGEING 
3.1 PRION PROTEIN EXPRESSION 
PrP expression was reported to be increased in the developing hamster brain (Sales et 
al. 2002). To determine if PrP expression also changes in the ageing murine brain, 
total brain homogenates from normal C57BL/6J mice at the age of 2, 4, 8, 16, 32 and 




Figure 8: Anti-prion protein (PrP) monoclonal MAb epitopes 
The epitopes recognized by the three anti-PrP MAbs 8B4, 8H4 and 8F9, are 
schematically depicted along the full-length mature murine PrP (MoPrP) sequence 
(residues 22-232). The MoPrP contains the conserved octarepeats, three α-helices and 
two β-sheets. The two N-linked glycosylation sites are located on residues 180 and 
196 as indicated. (Modified from Goh et al. 2007) 
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MAb 8B4, which recognizes an epitope between amino acid 37-45 on the mouse PrP 
sequence (Figure 8), binds only to full length PrP (Pan et al. 2002a; Wong et al. 
2003). It was found that the expression of various PrP species is differentially 
regulated with age (Figure 9). At week 2, MAb 8B4 reacted strongly with a major ~ 
37kDa band (Band 1) and weakly with a lower molecular weight band (~ 30kDa; 
Band 2) (Figure 9A). A third band (~ 28kDa; Band 3) was only apparent after week 8. 
As MAb 8B4 recognizes only the full length PrP, Bands 1, 2 and 3 are likely to 
correspond to the di-, mono- and un-glycosylated PrP isoforms respectively (Pan et al. 
2002a). Semi-quantitative densitometric analysis showed that increasing age elevated  
di-, mono-, and un-glycosylated PrP expression by ~80%, ~101% and ~110% 
respectively (Figure 9B). In addition, densitometric analysis showed Band 1 to be the 
predominant band during ageing, and that the intensity of Bands 2 and 3 are ~9% and 
~6% that of the higher molecular weight Band 1 respectively (Figure 9B). Extensive 
evidence has shown that PrP is variably glycosylated in vivo and it is widely believed 
that the di-glycosylated form is the most abundant in all species (Wiseman et al. 2005; 
Somerville et al. 2005; Pan et al. 2002a; Race et al. 2002). To ensure that the 
differential PrP expression is not the result of unequal protein loading, an actin 
immunoblot was included.  
 
Figure 9C corroborates the observations noted in Figure 9A. Using MAb 8H4, which 
recognizes amino acid 175-185 on the mouse PrP sequence (Figure 8), both full 
length as well as truncated PrP species can be detected. Although the epitope 
recognized by MAb 8H4 includes one potential N-linked glycosylation site, the 
antibody reacts equally well with recombinant PrP and native PrPC (Li et al. 2000; 
Pan et al. 2005a). This suggests that the presence of N-linked glycans on native PrPC 
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does not impede the binding of MAb 8H4. Unlike MAb 8B4, MAb 8H4 reacted 
strongly with the three protein bands (Bands 1 – 3) (Figure 9C) and Band 1 remains 
the predominant band during ageing. The intensities of Bands 2 and 3 are ~32% and 
~68% that of the higher molecular weight Band 1 (Figure 9D) respectively. Band 1 is 
likely to be the di-glycosylated full length PrP isoform. However, as MAb 8H4 binds 
both full length and truncated PrP isoforms, Band 2 is likely to comprise of full length 
mono-glycosylated and N-terminally truncated PrP isoforms, whereas Band 3 may 
consist of full length un-glycosylated and N-terminally truncated PrP isoforms. This 
heterogeneity of PrP isoforms in Bands 2 and 3 may account for the greater intensity 
of immunoreactivity observed in Figure 9C as compared to the same bands in Figure 
9A.  
 
In Figure 9C, an approximately 15kDa fragment was also detected at week 4 and this 
band (Band 4) remained apparent during ageing. This species reacted with MAb 8H4 
but not MAb 8B4, and is likely to be the reported N-terminally truncated C1 fragment 
found in non-diseased human (Chen et al. 1995; Jimenez-Huete et al. 1998) and 
murine (Pan et al. 2005b) brains. This is because the truncation occurs after the 
epitope sequence of MAb 8B4 (Chen et al. 1995). Densitometric analysis revealed the 
intensity of Band 4 to be approximately 11% that of Band 1 (Figure 9D). It was also 
found in Figure 9D that as age increased from 2 to 64 weeks, the expression of PrP 
Bands 1, 2, 3 and 4 increased ~55%, ~75%, ~277% and ~113% respectively. To 
ensure that the differential PrP expression is not the result of unequal protein loading, 










Figure 9 (Continued) 
PrP in 40µg of total brain proteins from 2, 4, 8, 16, 32 and 64 week old wild-type (n = 
3) mice was immunoblotted with anti-PrP (A) 8B4 and (C) 8H4. β-actin (bottom) was 
immunoblotted as a loading control. The apparent molecular weight is given in kDa. 
The optical densities of PrP Bands 1 (white), 2 (grey), 3 (black) and 4 (shaded) when 
immunodetected by anti-PrP (A) 8B4 and (C) 8H4 in the consecutive-aged brain 
samples of wild-type mice were quantified relative to the endogenous β-actin level for 
each sample lane in (A) and (C) using Kodak Digital Science ID Software. Results 
shown are the mean ± SEM of three independent samples per age group. (Extracted 
from Goh et al. 2007) 
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3.2 PROTEASE SENSITIVITY OF PRP SPECIES 
After demonstrating that PrP expression changes with age, the next step was to 
determine if the PrP species produced show altered sensitivity to protease cleavage 
during ageing. Equal quantities of total brain protein from individual murine brain at 
various ages were treated in the presence or absence of 0.2, 5, 25 and 50µg/ml 
proteinase K (PK). It can be seen from Figure 10A that 0.2µg/ml of PK has no 
profound effect on protease sensitivity since the level of PrP species at various ages, 
as defined by the intensity of immunoreactivity, remained essentially unchanged. 
However, increasing the PK concentration to 5µg/ml caused a substantial cleavage of 
the PrP species as shown by their digestion and the detection of only residual bands at 
around ~28kDa remaining in brain samples from weeks 4, 8 and 16 (Figure 10B). 
Complete digestion (and hence the lack of detection of any immunoreactive bands) of 
PrP species was only attained after incubating with 25 (Figure 10C) and 50µg/ml 
(Figure 10D) of PK. 
 
Where digestion of PrP species occurred, the same happened for actin. However, the 
difference in actin susceptibility to PK digestion at 0.2µg/ml is likely to be caused by 
reduced efficiency resulting from the low enzyme concentration. In general, Figure 
10 shows that the PrP species detected at old age (64 weeks) are equally susceptible to 
PK cleavage as that when young (2 weeks). This indicates that the PrP species 
detected during ageing did not develop protease resistance at the PK concentrations 












Figure 10 (Continued) 
PrP in total brain proteins from 2, 4, 8, 16, 32 and 64 week old wild type mice were 
treated in the presence (+) or absence (-) of (A) 0.2, (B) 5, (C) 25 and (D) 50µg/ml of 
PK before immunodetection with anti-PrP MAb 8H4. β-actin (bottom) was 
immunoblotted as a loading control. Results shown are a representation of 
independent samples from each age group. The apparent molecular weight is given in 
kDa. (Extracted from Goh et al. 2007) 
 
3.3 DISCUSSION 
In this study, it is observed that PrP expression is age-dependent in the developing 
murine brain from weeks 2 to 64. Such results are further corroborated by studies in 
the developing hamster brain (Sales et al. 2002), lending strong support for elevated 
PrP expression during the ageing process in mammalian brain. Interestingly, enhanced 
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PrP expression, in terms of an additional expression of two under-glycosylated full 
length PrP species and an N-terminally truncated PrP species, has previously been 
reported in the brain of ME7, 139A and 22L scrapie-infected mice (Pan et al. 2005b). 
Although the biological significance of changing PrP expression remains to be 
elucidated, its occurrence in both prion disease and ageing suggests that a similar 
pathological mechanism may underlie both processes, thus providing a link between 
ageing and prion pathogenesis. 
 
Prion disease is largely an age-related neurodegenerative disorder, and the associated 
pathogenic isoform of PrP (PrPSc) is resistant to PK digestion. It was determined if the 
PrP species detected at old age (64 weeks) spontaneously developed PK resistance. 
PK digestion assay examines if PrP is in the pathogenic form of PrPSc. Results in 
Figure 10 show that the PrP species expressed at all ages studied were equally 
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4. GLYCAN PROFILING OF PRION PROTEIN DURING NEURONAL 
AGEING 
4.1 GLYCOENZYMATIC ANALYSIS 
Figure 11 compares the glycans associated with the PrP species during ageing. PrP 
species in brain samples were incubated with PNGase F (peptide N-glycosidase F), 
Neuraminidase or a combination of both prior to immunoblotting with MAb 8B4 
(Figure 11, left-hand panel) or MAb 8H4 (Figure 11, right-hand panel). It is 
observed in Figure 11A that after being subjected to cleavage of any N-linked 
glycans by PNGase F, MAb 8B4 reacted with only one band at ~28kDa, indicating 
that this is the un-glycosylated full length PrP. In contrast, immunoblotting with MAb 
8H4 detected the ~28kDa band and two weaker lower molecular weight bands at ~20 
and ~15kDa after PNGase F digestion. These latter bands indicate variable truncation 
of PrPC, culminating in 2 major populations of N-terminally truncated PrPC species.  
 
Neuraminidase hydrolyzes N-acetyl-neuraminic acid (sialic acid) residues on proteins. 
Albeit less conspicuous, a consistently detectable increase in the mobility of PrP 
bands 1 and 2 was observed after treatment with neuraminidase. This decrease in 
molecular weight points to the presence of sialic acid residues on the PrP species 
(Figure 11B).  
 
Figure 11C presents a combined treatment of PrP species in the brain samples to 
PNGase F and neuraminidase. Immunoblotting with MAb 8B4 detected only one 
band at ~28kDa (Figure 11C, left-hand panel) while MAb 8H4 detected three bands 
at ~28, ~20 and ~15kDa (Figure 11, right-hand panel) after the glycosidase treatment. 
The distribution of PrP bands immunodetected after PNGase F and combined PNGase 
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F and neuraminidase treatment was similar. This indicates that the sialic acid residues 
found to be present on PrP may lie on the N-linked glycan branch.  
 
The specificity of the MAb 8B4 and 8H4 used in this study was verified in Figure 11. 
PrPC was not detected in 12 week old prion knockout (KO) brain sample treated in the 





Figure 11: Neuronal PrP sensitivity to peptide N-glycosidase F (PNGase F) and 
neuraminidase during ageing 
PrP in 40µg of total brain protein from 2, 4, 8, 16, 32 and 64 week old wild type mice 
was digested with (A) PNGase F, (B) neuraminidase or (C) combined PNGase F and 
neuraminidase prior to immunodetection with anti-PrP MAb 8B4 (left-hand panels) 
and 8H4 (right-hand panels). Brain homogenate from 12 week old prion knockout 
(KO) mice were similarly treated as a control. β-actin (bottom) was immunoblotted as 
a loading control. Results shown are a representative example of independent samples 
from each age group. The apparent molecular weight is given in kDa. (Extracted from 
Goh et al. 2007) 
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4.2 RECOMBINANT PRION PROTEIN EXPRESSION 
Since PrP expression alters with age, it becomes crucial to normalize the lectin results 
with the amount of PrP actually present in the brain homogenates. This was 
determined by performing sandwich ELISA alongside known quantities of 
recombinant mouse PrP. Recombinant PrP was cloned into the pEXP1-DEST 
expression vector (Invitrogen, CA, USA) as shown in Figure 12. A nickel-based 
column which binds the polyhistidine tag of the recombinant protein was employed to 
purify the recombinant PrP expressed in Origami™ (DE3) competent cells. The 
effectiveness of the expression process was assessed by immunoblotting with anti-PrP 
MAb 8H4 (Figure 13).  
 
 
Figure 12: Vector map of pEXP1-DEST used for expression cloning of 
recombinant mouse PrP 
The diagram shows the site of recombination of the murine PrP gene, with the 
consequent replacement of the chloramphenicol resistance (CmR) gene and the ccdB 
gene. Recombinant mouse PrP gene is expressed as a tagged protein with 
polyhistidine (6xHis), XpressTM epitope and enterokinase cleavage site at the N-





An intense ~28kDa band was detected 2 hours after the addition of 1mM IPTG 
(Figure 13). A faint band of the same size was observed in the absence of IPTG, and 
this corresponds to the basal expression of the recombinant protein. Similar results 
were obtained when IPTG was allowed to incubate for 3 hours.  
 
 
Figure 13: Recombinant murine PrP expression 
Recombinant PrP expression was induced by the addition of 1mM IPTG. The 
apparent molecular weight is given in kDa. 
4.3 LECTIN ELISA 
An anti-PrP MAb-lectin ELISA (Pan et al. 2002a, 2005a) was set up to better define 
the pattern of glycans attached to full length and truncated PrPC species during the 
ageing process. Lectins are powerful tools for this purpose as they can recognize and 
bind glycan moieties of glycoproteins in a highly specific manner. Firstly, full length 
PrP was immunodepleted from the brain homogenates using MAb 8B4 in order to 
obtain N-terminally truncated PrP species (Pan et al. 2002a). The efficiency of this 
immunodepletion process was examined by immunoblotting with MAb 8H4 (Figure 
14). It is observed that there was a significant decrease in detectable PrP species after 




Figure 14: Immunodepletion of full length PrP 
Full-length PrP in 500ug of total brain homogenate from 2, 4, 8, 16, 32 and 64 week 
old wild-type mice were immunoprecipitated (IP) with MAb 8B4, followed by 
immunodetection with anti-PrP 8H4. The apparent molecular weight is given in kDa. 
Result shown is a representation of independent samples from each age group. 
 
The lectin ELISA was carried out by immobilizing either anti-PrPC 8B4 or anti-PrPC 
8F9 on a solid phase to capture full length or N-terminally truncated PrP species in 
the brain homogenates respectively. After extensive washings, a panel of 19 biotin-
conjugated lectins (Table 1) was added individually to react with the affinity-captured 
PrP species.  
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Table 1: Sugar specificity of lectins used 
(Extracted from Goh et al. 2007) 
 
The binding of individual biotinylated lectins to the full length and truncated PrP 
species in brain samples of various ages is shown in Figures 13 and 14 respectively, 
and a summary of the lectins immunoreactivity is given in Table 2. The lectins listed 
in Table 2 are organized according to their common sugar specificity for ease of 
comparison.  
 
It was observed that the binding of lectins that recognize N-acetylgalactosamine 
(GalNAc) (GSLI, SJA and VVA) (Figure 15C), GlcNAc (GSLII, LEL, STL and 
SWGA) (Figure 15D), galactose (ECL, PNA, GSLI and SJA) (Figure 15C), 
mannose (GNL and LCA) and glucose (LCA) (Figure 15A) on the full length PrP 
increased with age. Greater reactivity of UEAI, but reduced binding of AAL, to the 
captured PrP species as age increases was also detected (Figure 15B). Although both 
UEAI and AAL recognizes fucose, the latter reacts only with fucose linked (α-1,6) to 
GlcNAc and fucose linked (α-1,3) to N-acetyllactosamine-related structures. This 
suggests a rising presence of α-linked fucose (such as α-1,2 linked fucose to which 
UEAI preferentially binds) to structures other than either GlcNAc or N-
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acetyllactosamine on full length PrP during ageing. From Figure 15C, it was 
observed that the binding of full length PrP to Jacalin differed from that to PNA. This 
is because PNA binds preferentially to galactosyl (β-1,3) GalNAc on a non-sialylated 
structure. In line with this, a low level of SNA immunoreactivity that is not age-
dependent was seen in Figure 15E. Additionally, a growing content of complex 
oligosaccharides (a mixture of bi-, tri- and tetra-antennary) was observed as shown by 




















Figure 15 (Continued) 
Brain homogenate PrPC in 2, 4, 8, 16, 32 and 64 week old wild type mice was 
captured using anti-PrP 8B4 prior to detection with a panel of biotinylated lectins by 
sandwich enzyme-linked immunosorbent assay (ELISA). The level of captured PrP in 
each sample was determined and normalized using several known quantities of 
recombinant mouse PrP as previously described (Wong et al. 2003). Results are 
expressed as the mean ± SEM of duplicate assays for individual samples (n = 3). * P 
< 0.05, ** P < 0.01, *** P < 0.001 using One-Way ANOVA followed by Tukey’s 
Honestly Significant Difference test. ConA, Concanavalin A; LCA, Lens Culinaris 
Agglutinin; GNL, Galanthus Nivalis Lectin; Jacalin, Jacalin; AAL, Aleuria Aurantia 
Lectin; PNA, Peanut Agglutinin; UEAI, Ulex Europaeus Agglutinin I; GSLI, 
Griffonia Simplicifolia Lectin I; ECL, Erythrina Cristagalli Lectin; GSLII, Griffonia 
Simplicifolia Lectin II; VVA, Vicia Villosa Lectin; WGA, Wheat Germ Agglutinin; 
SJA, Sophora Japonica Agglutinin; SWGA, Succinylated Wheat Germ Agglutinin; 
DSL, Datura Stramonium Lectin; SNA, Sambucus Nigra Lectin; LEL, Lycopersicon 
Esculentum Lectin; PHA-E+L, Phaseolus vulgaris Agglutinin; STL, Solanum 
Tuberosum (Potato) Lectin. (Adapted from Goh et al. 2007) 
 
Figure 16 compares the binding of the panel of lectins to truncated PrP species as age 
increases. With the exception of LCA, DSL, VVA and WGA, the reactivity of the 
remaining lectins to truncated PrP species are in contrast to full length PrP. It is 
observed that the binding of lectins that recognize galactose (PNA, GSLI and SJA) 
(Figure 16C), GalNAc (GSLI and SJA) (Figure 16C) and GlcNAc (GSLII and LEL) 
(Figure 16D) on the truncated PrP species decreased with age. Just as contrasting 
binding was observed in the case of full length PrP, the binding of truncated PrP 
species to GSLI differed from that to VVA (Table 2). VVA recognizes both α- and β-
linked terminal GalNAc, whereas GSLI appears to be specific only for α-linked 
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GalNAc. The increased immunoreactivity of VVA (Figure 16C) towards truncated 
PrP species therefore suggests either a greater presence or availability of β-linked 
terminal GalNAc on truncated PrP during ageing. Reduced reactivity of UEAI to 
truncated PrP as age increases is also detected (Figure 16B). This, in addition to the 
lack of significant changes in AAL reactivity towards the ageing truncated PrP, 
suggests a reduced availability of α-linked fucose to structures other than either 
GlcNAc or N-acetyllactosamine on truncated PrP during ageing. Also on a decline are 
the complex oligosaccharides, as shown by decreased reactivity of PHA-E + L 
towards the ageing truncated PrP (Figure 16F). Correspondingly, an increase in the 
presence of glucose and mannose is detected as shown by the elevated reactivity of 
ConA and LCA towards the ageing truncated PrP (Figure 16A).  
 
Truncated PrP species also display differential sialylation during ageing. Reactivity of 
truncated PrP with SNA was observed to be decreased during ageing (Figure 16E), 
indicating a reduced availability of sialic acid residues linked to terminal galactose in 
either an α-2,6 or an α-2,3 manner. This is in agreement with the overall reduction in 
galactose detected by PNA, GSLI and SJA as observed in Figure 16C. Furthermore, 
there was no detectable binding of truncated PrP species to both WGA and Jacalin 
after weeks 8 and 16, respectively (Figure 16D and 16C). 
 
In summary, the lectin analysis suggests that ageing full length PrP has either an 
increasing content or an increasing exposure of galactose, GalNAc, GlcNAc, fucose, 
mannose and glucose. On the contrary, either a decreasing content or availability of 
galactose, GalNAc, GlcNAc, fucose and sialic acids is observed on truncated PrP 
during ageing. Unlike previous study of the glycosylation profile of PrPC isolated 
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from Syrian hamster brains (Rudd et. al. 1999), results from this current study provide 

















Figure 16 (Continued) 
Brain homogenate PrPC in 2, 4, 8, 16, 32 and 64 week old wild type mice was 
subjected to immunoprecipitation using anti-PrP 8B4 to remove the full length PrP 
before addition to anti-PrP 8F9 coated plated. The captured truncated PrP were 
detected with a panel of biotinylated lectins by sandwich enzyme-linked 
immunosorbent assay (ELISA). The level of captured PrP in each sample was 
determined and normalized using several known quantities of recombinant mouse PrP 
as previously described (Wong et al. 2003). Results are expressed as the mean ± SEM 
of duplicate assays for individual samples (n = 3). * P < 0.05, ** P < 0.01, *** P < 
0.001 using One-Way ANOVA followed by Tukey’s Honestly Significant Difference 
test. ConA, Concanavalin A; LCA, Lens Culinaris Agglutinin; GNL, Galanthus 
Nivalis Lectin; Jacalin, Jacalin; AAL, Aleuria Aurantia Lectin; PNA, Peanut 
Agglutinin; UEAI, Ulex Europaeus Agglutinin I; GSLI, Griffonia Simplicifolia Lectin 
I; ECL, Erythrina Cristagalli Lectin; GSLII, Griffonia Simplicifolia Lectin II; VVA, 
Vicia Villosa Lectin; WGA, Wheat Germ Agglutinin; SJA, Sophora Japonica 
Agglutinin; SWGA, Succinylated Wheat Germ Agglutinin; DSL, Datura Stramonium 
Lectin; SNA, Sambucus Nigra Lectin; LEL, Lycopersicon Esculentum Lectin; PHA-
E+L, Phaseolus vulgaris Agglutinin; STL, Solanum Tuberosum (Potato) Lectin. 




































































Glycosylation and glycation are the enzymatic and non-enzymatic attachment of 
carbohydrates to a protein respectively. Glycation differs from glycosylation in that 
the former results in the formation of irreversible advanced glycation end products 
(AGEs). In line with this, glycation cannot be reversed by the effects of 
endoglycosidase action such as PNGase F. To date, there are no known mammalian 
enzymes that can deglycate proteins. PNGase F treatment resulted in the complete 
removal of saccharides from PrPC (Figure 11A), indicating that PrPC glycation is 
non-existant. Hence the presence of AGEs was not tested using antibodies to AGEs.   
 
The specificity of the lectin ELISA has been examined in earlier studies (Pan et al. 
2002a, 2005a). The authors showed that: (i) the binding of biotinylated lectins to 
MAb-captured PrP species is PrP-dosage dependent and is in proportion to the 
quantity of immobilized PrP; (ii) the binding of biotinylated lectins to MAb-captured 
PrP can be efficiently inhibited by the appropriate sugars; and (iii) the biotinylated 
lectins do not react with captured PrP pre-treated with PNGase F. Additionally, Pan 
and co-workers (2005a) employed titration experiments to identify the concentration 
of captured MAb at the linear portion of the PrP binding curve with a specific 
quantity of brain homogenate. Therefore, the quantity of plate-coated MAb is limiting, 
whereas the level of PrP species is in excess. This ensures that the quantity of 
captured PrP species from various samples is similar. Thus the differences in ELISA 
readings were not a result of quantitative differences in the amount of captured PrP, 
but rather reflect the differences in lectin binding between the different age groups. 
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Changes, for instance increment, in lectin immunoreactivity observed in Figures 14 
and 15 may be attributed to increase in PrP expression and/or elevated PrP 
glycosylation during ageing. However, PrP has been established to be variably 
glycosylated by two, single or no oligosaccharide chains. This means that there is no 
linear relationship between the attachment of the glycan chains and the amount of PrP 
present. As such, accurate determination of the glycan profile of PrPC depends on 
normalizing the immunoreactivity of various lectins with the amount of PrP present in 
each brain sample.  
 
In this study, it is seen that full length PrP displayed elevated content or availability of 
galactose, GalNAc, GlcNAc, fucose, mannose and glucose, in the ageing mouse brain. 
These observations are consistent with the parallel increase in complex sugar 
formation on the ageing full length PrPC, which involves the addition of such residues 
as GlcNAc at branch points. In line with this, previous studies have demonstrated that 
the N-linked glycans found in PrPC are of the complex type and that they contain core 
fucosylation, terminal sialic acids and penultimate galactose with terminal bisecting 
GlcNAc residues (Endo et al. 1989; Haraguchi et al. 1989). Of particular interest, the 
elevated prevalence of complex oligosaccharides found on full length PrP during 
ageing bears resemblance to the glycosylation changes found on PrPSc when 
compared to PrPC. Rudd and co-workers found that PrPSc displayed elevated levels of 
tri- and tetra-antennary glycans compared to PrPC (Rudd et al. 1999). This change, 
they found, was consistent with a down-regulation in the activity of GlcNAc 
transferase-III (GnT-III), which inhibits further branching of the sugars by preventing 
the processing by GnT-II, IV or V. Whether the change in complex sugar formation 
on ageing full length PrPC is caused by a down-regulation of GnT-III or other relevant 
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glycosyltransferases remains to be established. Prion strain characteristics such as 
glycoform patterns are sustained during disease transmission. The occurrence of 
enhanced complex sugar formation on ageing PrPC and on PrPSc suggests that this 
particular sub-population of glycosylated PrPC may be preferentially susceptible to 
pathogenic transition to PrPSc, and as such, a relationship may exist between ageing 
and prion pathogenesis. 
 
In a recent comparative study by Pan and colleagues (2005a), immunoreactivity of 
Ricinus communis agglutinin I (RCA-I) towards full length PrP species in sporadic 
and variant CJD was reported to be enhanced in contrast to non-CJD controls. RCA-I 
binds preferentially to oligosaccharides terminating in β-galactose, though it also 
reacts weakly with α-galactose and GalNAc. Together with the reported observation 
that the increased RCA-I binding in sporadic and variant CJD is mostly associated 
with the PK-resistant PrP species, these results indicate elevated galactose on full 
length PrPSc in sporadic and variant CJD over its non CJD controls which contain 
mostly, if not solely, PrPC isoform. This difference in the glycosylation pattern 
between full length PrPC in non-CJD controls and full length PrPSc in sporadic and 
variant CJD cases provides additional support for the view that a link possibly exists 
between the glycosylation changes on PrPSc compared to PrPC, and that on the ageing 
full length PrPC, because age dependent elevation in galactose on PrPC was also 
observed in this current study. Evidence for the latter is provided by the enhanced 
immunoreactivity of ECL, PNA, GSLI and SJA towards the full length PrPC as age 
increased (Figure 15C). 
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PrPC undergoes endoproteolytic cleavage under normal physiological conditions, 
although the function and significance of such truncation remains to be resolved. 
Figure 9 shows that PrPC indeed undergoes truncation as reflected by the detection of 
an approximately 15kDa band (the estimated MW of unglycosylated N-terminally 
truncated PrPC between residue 111 and 112) by MAb 8H4 and not MAb 8B4. 
Furthermore, it is observed that PrPC truncation occurs at more than one site (Figure 
11). However, there is sufficient preference for certain cleavage sites resulting in the 
detection by MAb 8H4 of two main populations of unglycosylated truncated PrPC (of 
approximately 20 and 15 kDa) after PNGase F digestion. Further evidence 
substantiating such variable endoproteolytic cleavage of PrP is provided by studies by 
Pan and colleagues (2002a). Using two-dimensional gel electrophoresis and a panel of 
anti-PrP MAb, they showed that separation of PrPC species from human brain into 
multiple protein spots, each representing a distinct PrPC species, are attributed to the 
presence of full-length and two major truncated forms, as well as the myriad of 
glycoforms attached to these species. Additionally, using immunoblot analysis of 
deglycosylated samples from human brain cortex and cerebellum, Jimenez-Huete and 
co-workers (1998) identified this second cleavage to occur between residues 80 and 
100.  
 
PrPC truncation is suggested to play a role in the pathogenesis of prion disease and 
may contribute to the generation of prion strain diversity, in part due to its variable N-
linked glycosylation (Pan et al. 2002b; Brown and Besinger 1998; Ehlers and 
Diringer 1984; Kimberlin and Walker 1986). For this reason, the glycan profile on N-
terminally truncated PrPC was also analysed.  
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Results from the lectin ELISA in this study (Figure 16) reveal a markedly different 
glycosylation profile on truncated PrPC from its full length counterpart. An age-
dependent decrease in the content or availability of galactose, GalNAc, GlcNAc, 
fucose and sialic acids was observed on truncated PrPC. These observations are 
consistent with what appears to be a simplification of the glycosylation process in 
truncated PrPC during ageing, with a decrease in the immunoreactivity of PHA-E+L 
and a corroborative increase in either the availability or exposure of glucose and 
mannose. Taken together, results in this study indicate that differential glycosylation 
occurs on full length and truncated PrPC. These results are corroborated by distinct 
glycan profile on human full length and truncated PrPC reported by Pan and 
colleagues (2002a). Using two-dimensional gel electrophoresis, they observed greater 
alteration of the pI of full length PrPC species compared to the diglycosylated N-
truncated PrPC following neuraminidase treatment. This was attributed to the 
enhanced presence or availability of sialic acid residues to neuraminidase digestion on 
full length PrPC. Interestingly, results from this current study showed an upward 
detection of SNA immunoreactivity (Figure 15E) despite a lack of significant 
difference in the binding of SNA to full length PrPC with increasing age. At the same 
time, a rapid decline in the level of sialic acid detected by SNA was observed in the 
case of truncated PrPC between 2 and 8 weeks (Figure 16E). In addition, results from 
lectin ELISA conducted by Pan and colleagues as well as in this study showed the N-
truncated PrPC to display elevated levels of (α-1,3)- and (α-1,6)-fucose and mannose 
residues (Pan et al. 2002a). Figure 15B shows that the relative binding of AAL 
decreased from ~7 to ~2.9 on increasingly aged full length PrPC. AAL binding on 
increasingly aged truncated PrPC, on the other hand, appeared to fluctuate within 
levels of ~140 and ~306 (Figure 16B). Levels of Con A, LCA and GNL, all of which 
 74 
recognise mannose residues, on full length PrPC were well below that detected on its 
truncated counterpart (Figures 15A and 16A).These results suggest that glycosylation 
is protein specific.  
 
Protein specific glycosylation has previously been reported in cases of Alzheimer ’s 
disease (AD), another age-related neurological disorder displaying amyloid 
fibrillization and formation of aggregates. Sáez-Valero and colleagues (1999) showed 
that acetylcholinesterase glycosylation is altered in the AD brain and that these 
changes are attributed to altered distribution of the various acetylcholinesterase 
isoforms in the brain. In addition, Kanninen and co-workers (2004) identified 
enhanced glycosylation of glial fibrillary acidic protein and simultaneous decline in 
glycosylation of collapsin response mediator protein 2 which is involved in the 
assembly and polymerization of microtubules, a known participant of neurofibrillary 
tangles in AD. It is possible that such post translational protein modifications serves 
as a molecular switch, activating or deactivating cellular events, altering the 












RESULTS III: GLYCOTRANSFERASE EXPRESSION 









5. RESULTS III: GLYCOTRANSFERASE EXPRESSION DURING 
NEURONAL AGEING 
To explore the functional relationship between the glycan diversity on PrPC and the 
expression profile of glycosyltransferases and glycosidases during ageing, microarray 
was carried out. 
5.1 GLYCAN-MICROARRAY 
A customized gene array system containing probe sets to analyse the expression of 
approximately 1000 mouse transcripts relevant to glycosylation was used to 
understand the complete expression profile of known glycosyltransferases and 
glycosidases during ageing. This GLYCOv3 gene chip is provided by The 
Consortium for Functional Glycomics (Comelli et al. 2006). The complete list of 
genes is provided in the appendix.  
 
Results in Table 3 show that 17 of these genes are differentially expressed between 
young (2 weeks) and aged (82 weeks) brains. The expression of 15 genes including 
those encoding the carbohydrate binding proteins (CBPs) such as C1q receptor, 
Versican , Neurocan, Macrophage mannose receptor, Vasicular cell adhesion 
molecule-1 and Neural cell adhesion molecule, the glycan transferases such as UDP-
glucuronosyltransferase 8 and Galactose-3-O-Sulfotransferase-1, the chemokine 
protein tyrosine phosphatase (PTP), the cytokine Interferon-γ-receptor 2, the growth 
factors bone morphogenetic protein 4, fibroblast growth factor 13, Met proto-
oncogene and prepro-insulin-like growth factor 2, and platelet derived growth factor 
receptor-β was reduced in 82 week-old brains compared to the levels in 2 week-old 
brains (Table 3). In contrast, the expression of two genes namely, Dectin-1 and the 
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GalNAc transferase Galnt 19 was elevated in 82 week-old brains compared to the 
levels in 2 week-old brains (Table 3).  
Table 3: Differentially expressed genes between 2 week-old and 82 week-old 
brains from GLYCOv3 Microarray Analysis 
List of genes (A) down- and (B) up-regulated by at least 2-fold in 82 week-old brains 
compared to 2 week-old brains. 
 
(A) Down-regulation  
Accession 
Number Gene name 
log(Fold 
Change) 
     
Carbohydrate binding protein (CBP)   
AF081789 C1q receptor - Long trans -1.735 
NM_019389 Versican (CSPG2, PG-M) -1.145 
X84727 Neurocan -1.014 
Z11974 Macrophage mannose receptor -1.098 
NM_011693 VCAM-1 (CD106) - Long Trans -1.050 
NM_008478 N-CAM (CD56) -1.010 
     
Glycan transferase   
NM_011674 UDP-glucuronosyltransferase 8 (Ugt8) Short transcript -1.524 
NM_016922 Gal3ST-1 -1.092 
     
Chemokine    
NM_021464 PTP - Long Trans -1.293 
     
Cytokine    
NM_008338 INF-gamma R2 -1.124 
     
Growth factors & Receptors   
NM_007554 BMP4 -1.521 
NM_010200 FGF13 -1.205 
NM_008591 Met -1.013 
NM_010514 Prepro-insulin-like GFII -1.053 
NM_011058 PDGFR beta -1.315  
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(B) Up-regulation  
Accession 
Number Gene name 
log(Fold 
Change) 
     
Carbohydrate binding protein (CBP)   
AF262985 Dectin-1 (clecsf12) 1.663 
     
Glycan transferase   
NM_030166.1 ppGalNAc T19 (Galnt19), aka GalntL2 Long transcript 1.089  
 
To facilitate inferences regarding which cellular pathways and functional processes 
were altered, the categories in the Biological Process, Cellular Component and 
Molecular Function ontologies of Gene Ontology (GO) hierarchical database 
(http://www.geneontology.org/)  that were represented by the 17 identified genes were 
determined (Table 4). Major biological processes that were found to be affected by 
the downregulated genes in aged (82 week old) mouse brain include cell adhesion, 
cell differentiation, glycolipid biosynthesis, protein amino acid phosphorylation, 
myelination and multicellular organismal development. These changes correspond to 
perturbations of ATP and calcium ion binding, hyaluronic acid and sugar binding, 
growth factor and glycosyltransferases activity, and kinase activity such as protein 
tyrosine kinase activity. Affected immune responses such as inflammatory and innate 
immune response were associated with upregulated genes in the aged (82 week old) 
mice brain by biological processes attributed to the sugar binding ability of proteins 
such as Dectin-1, which is a major β-glucan receptor expressed on leukocytes (Taylor 




Table 4: Functional categories/pathways altered with ageing 
Gene categories and pathways are listed under the direction of change of the 
differentially expressed genes. Gene categories and pathways were determined from 
the Gene Ontology Database (Molecular function, Biological process and Cell 









In chapter 4, the glycan profile on ageing PrPC was determined using lectins, which 
have the ability to recognise and bind sugar moieties in a linkage-specific manner. 
The reactivities of these lectins include mannose, glucose, fucose, galactose, GalNAc, 
GlcNAc and sialic acids. The levels of these sugars attached to full length and 
truncated PrPC were observed to be differentially altered with increasing age. The 
structural diversity of N-linked glycans on glycoproteins is determined by the 
expression and regulation of glycan-modifying enzyme activities, and the availability 
of the relevant donor / acceptor substrates. Gene expression potentially exerts a major 
influence on post-translational modifications as shown by the spatial and temporal 
distribution of many glycosyltransferases and glycosidases (Ishii et al. 2007; Zhou et 
al. 1998; Kono et al. 1996; Yoshida et al. 1995). Microarray approach was thus 
employed in this study to determine the global, systemic changes to the expression of 
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these enzymes, which may in turn enable predictions to be made regarding the glycan 
pattern formed (Comelli et al. 2006).  
 
The sugar specificity of each lectin studied in chapter 4 and the contributory 
glycosyltransferases involved are shown in Table 5.  
Table 5: Glycosyltransferases responsible for glycan structures formed on PrPC. 
List of glycosyltransferases that transfers (A) mannose, (B) glucose, (C) fucose, (D) 
galactose, (E) GalNAc, (F) GlcNAc and (G) sialic acid to the growing oligosaccharide 















The genes encoding these enzymes are among the ~1000 mouse transcripts probed on 
the GLYCOv3 gene chip. Details of the glycosyltransferases involved in the 




The lectins ConA and LCA have sugar specificity for α-linked mannose residues 
(Finne and Krusius 1982). They are able to recognize and bind mannose that are 








The mannosyltransferases involved are ALG2, ALG3, ALG9 and ALG12. These α-
linked mannose residues are often found in the core oligosaccharide structure of N-
linked glycoproteins. GNL shows preferential binding toward structures containing 
(α-1,3)-linked mannose residues (Shibuya et al. 1988). The mannosyltransferases that 
catalyse the synthesis of this glycosidic linkage are ALG2 and ALG3.  
 
Glucose 
Αlpha-linked glucose residues such as (α-1,2)- and (α-1,3)-glucose can be recognised 
and bound by lectins ConA and LCA. These sugars are formed by the action of 
glucosyltransferases such as ALG10, ALG6 and ALG8 (Figure 18). 
 
 




AAL preferentially binds to fucose linked (α-1,6) to GlcNAc or to fucose linked (α-
1,3) to N-acetyllactosamine. These glycosidic linkages may be formed by 
fucosyltransferases as indicated in Table 5C. Fucosyltransferases Fut 4, 7, 9, 10 and 
11 transfer the fucose component of UDP-fucose to N-acetyllactosamine, while Fut 8 





Figure 19: Schematic representation of fucosyltransferase activity 
 




Galactose residues are recognised by five lectins in this study. Specifically, while SJA 
binds to any terminal galactose, GSLI recognises only α-linked galactose residues. 
The latter may be formed by galactosyltransferases a1,3GalT and a4GalT which adds 
galactose in a (α-1,3) and (α-1,4) linkage, respectively, to a galactose residue on the 
growing chain. Jacalin and PNA are highly specific for galactose residues linked (β-
1,3) to GalNAc. On the other hand, ECL preferentially recognises galactose linked (β-
1,4) to GlcNAc. This reaction involves the action of UDP-Gal:betaGlcNAc beta 1,4-
galactosyltransferases (b4GalT) and is depicted in Figure 20. 
 
 









Alpha- and beta-linked GalNAc are specifically recognised by GSLI and VVA 
respectively. With a broader range of specificity, SJA binds any terminal GalNAc 
residues. GalNAc-transferases catalyse these glycosidic bond formations by 
transferring the GalNAc component of UDP-GalNAc to the growing chain of 
glycoproteins (Figure 21). The resultant N-glycan with terminal GalNAc may be 
further sulphated, forming sulphated N-linked glycans such as those associated with 
pituitary glycoprotein hormone lutropin. 
 
 





GlcNAc residues are broadly recognised by the lectins GSLII, LEL, STL, WGA and 
SWGA. DSL, on the other hand, is highly specific for (β-1,4)-linked GlcNAc 
oligomers. GlcNAc residues are involved in N-glycan diversification as it is added to 
the branching points. The enzymes responsible for these sugar modifications are the 
GlcNAc transferases such as the mannoside acetylglucosaminyltransferases (Mgats). 
These enzymes can result in the processing of N-glycans with high-mannose 
structures to those with hybrid or complex structures (Figure 22). Complex 
oligosaccharides can adopt bi-, tri-, or tetra-antennary structures, and they can be 








Sialic acids linked (α-2,6) and (α-2,3) to terminal galactose are specifically recognised 
by SNA. These glycosidic linkages are formed by β-galactoside (α-2,6) and (α-2,3) 
sialyltransferases respectively (Figure 23). The resultant sialylated N-linked glycan 
has previously been reported on follicle stimulating hormone. 
 
 




Microarray results in this study showed no differential transcription of genes involved 
in N-glycosylation between young and aged murine brains, such as the GlcNAc 
transferases-II, -IV and -V involved in complex sugar formation (as otherwise 
expected). One possibility is that this lack of correlation of gene transcription with the 
structures of PrPC glycans formed could be due to the strain differences between 
B6.129SV (in microarray analysis) and C57BL/6J (in glycan structural studies) 
background. Due to experimental difficulty in obtaining animals of the same 
C57BL/6J strain, B6.129SV mice brain samples were kindly provided by Dr Roberto 
Cappai and Dr Joe Ciccotosto of University of Melbourne. B6.129SV mice have a 
genetic background derived from 129/Sv and C57BL/6J mice, and differ genetically 
from C57BL/6J mice by ~1%. However, Northern blot analysis showed that the gene 
expression is unlikely to be affected by strain differences between C57BL/6J and 
B6.129SV mice (Satoh et al. 2000). Nonetheless, because microarray functions as a 
screening tool for assaying transcript abundance, the microarray results observed in 
this study require follow-up analysis using techniques such as real-time polymerase 
chain reaction (PCR) and Northern Blot for confirmation and functional validation.  
 
It is also conceivable that altered enzymatic activities rather than gene expression of 
these glycan-modifying enzymes may be responsible for the differential pattern of 
glycosylation observed between young and aged PrPC. To understand the mechanism 
underlying the control of glycosylation of many glycoceuticals, Takamatsu and 
colleagues showed that the activities of six branch-forming glycosyltransferases 
roughly corresponded to the structures of the cell surface complex sugar chains 
formed (Takamatsu et al. 2005). Alternatively, metabolic defects during ageing may 
indirectly cause reduced substrate availability to these glycosyltransferases, thus 
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imposing secondary effects on N-glycosylation. For instance, a reduced ability to 
metabolize galactose may result in decreased levels of available UDP-galactose, 
consequently impeding galactosyltransferase function. Such connection between 
metabolism and post-translational modification highlights the complexicity involved 
in maintaining homeostasis at cellular and tissue levels. 
 
In the present study, microarray analysis showed that three glycan modifying enzymes 
exhibited differential gene expression pattern between young (2 week-old) and aged 
(82 week-old) mice brain. The expression of UDP-glucuronosyltransferase 8 (Ugt8) 
and Galactose-3-O-Sulfotransferase-1 (Gal3ST-1) were reduced in 82 week-old 
compared to that in 2 week-old mouse brain. In contrast, enhanced gene expression of 
the GalNAc transferase Galnt 19 was detected in 82 week-old mouse brain compared 
to 2 week-old mouse brain (Table 3). Unfortunately, these three enzymes are not 
responsible for the differential PrPC N-linked glycosylation observed during ageing. 
Galnt 19 belongs to a family of polypeptide N-acetylgalactosaminyl transferases 
(ppGalNAcT) which synthesizes the GalNAcαThr/Ser linkage commonly occurring in 
the “mucin type” O-linked glycans (Ten Hagen et al. 2003; Young et al. 2003). 
 
Ugt8 is a galactosyl-transferase synonymously termed Cgt that is involved in 
glycosphingolipid biosynthesis. This enzyme initiates the synthesis of 
galactosylceramide by the addition of UDP-galactose to ceramide (Coetzee et al. 1996; 
Sprong et al. 1998).  The galactocerobrosides produced are major components of the 
myelin sheath facilitating nerve conduction, thus explaining the high expression of 
Ugt8 in oligodendrocytes and Schwann cells (Katayama et al. 2006). 
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Another major component of oligodendrocytes and myelin is galactosylceramide 
sulphate, which is synthesized by a family of galactosylceramide sulfotransferase. 
This group of enzymes include Gal3ST-1 (also known as CST for cerebroside 
sulfotransferase). The tissue-specific expression of this enzyme accounts for the 
selective production of galactosylceramide sulphate, by the transfer of a 3’-
phosphoadenylyl sulphate to galactosylceramide, in tissues such as the stomach, small 
intestine and brain (Hirahara et al. 2000). The sulfoglycolipids produced by CST play 
a role in modulating physical interactions such as with extracellular matrix proteins 
and cellular adhesive receptors, due in part to electrostatic interaction between the 
negatively charged sulfoglycolipids and the positively charged amino acid side chains 
of proteins (Vos et al. 1994). These properties and their high expression in 
oligodendrocytes and myelin suggest a role of Gal3ST-1 produced galactosylceramide 
sulphate in myelin formation. 
 
With ageing, altered pathways or processes were identified to include a down-
regulation of myelination and nerve conduction, signal transduction via the MAPK 
cascade and receptor protein tyrosine kinase signalling pathway, and receptor protein 
tyrosine phophatase activity (Table 4). Receptor protein tyrosine phosphatase plays 
essential roles in axonal outgrowth/guidance (Stepanek et al. 2005), which was also 
found to be reduced (Table 4). Consequently, brain and nervous system development 
is compromised. Taken together, these results suggest down-regulated neuronal 
























6.1 OVERALL CONCLUSION 
Ageing results in significant changes in the expression profiles of PrPC species in the 
normal murine brain. At week 2, only three protein bands are detectable. These 
consist of the fully glycosylated (Band 1) and unglycosylated (Band 3) full length 
PrPC species as well as a mixture of monoglycosylated full length and variably N-
truncated and glycosylated PrPC species (Band 2). Whilst the fully glycosylated full 
length PrPC remains the predominant species detected throughout the ages studied, the 
expression of N-terminally truncated and under-glycosylated (mono- and un-
glycosylated) full length PrPC species increases with age. These bands collapse into a 
single unglycosylated full length PrPC species (28kDa) and two populations of 
distinctively N-terminally truncated PrPC species (20 and 15kDa) following PNGase F 
treatment. Together with the use of anti-PrP MAb targeting the N- and C-terminal of 
PrP, these results indicate that differences in the N-linked glycans and variable 
endoproteolytic cleavage cause the changes in detectable protein band intensities with 
increasing age.  
 
Interestingly, accumulation of under-glycosylated full length and N-terminally 
truncated PrP species has recently been speculated to be a general characteristic of 
most prion diseases (Pan et al. 2005b). It was found that in the brain of mice infected 
with either 139A, ME7 or 22L strain of mouse scrapie prion, there was an 
accumulation of under-glycosylated full length and N-terminally truncated PrP 
species that partitioned with PrPSc aggregates in a 10 to 60% sucrose gradient (Pan et 
al. 2005b). However, the mechanisms by which ageing and prion infection cause the 
accumulation of under-glycosylated and N-terminally truncated PrPC are not clear. 
Attributes to elevated PrP expression or a decrease in the degradation of aberrant PrP 
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remain at best speculative. Nonetheless, this accumulation of under-glycosylated and 
N-terminally truncated PrPC in both ageing and prion infection suggest a first link that 
ageing PrPC may be associated with prion disease development.  
 
Aberrant protein degradation is dependent upon the efficiency of the ubiquitin-
proteasome system. However, proteasome impairment has been reported in prion 
disease (Kang et al. 2004; Kristiansen et al. 2007) as well as in other 
neurodegenerative disorders such as Alzheimer’s disease (Keller et al. 2000) and 
Parkinson’s disease (McNaught et al. 2001). Kristiansen and colleagues reported that 
upon prion infection, oligomers of PrPSc could cause proteasomal impairment by 
inhibiting the catalytic core β-subunits of the 26S proteasome (Kristiansen et al. 2007). 
The compromised proteasomal function becomes overwhelmed by the increasingly 
ubiquitinated PrP species detected in scrapie-infected brains (Kang et al. 2004), 
resulting in cytosolic PrP accumulation (Ma and Lindquist, 2002) and aggregation and 
ultimately, neurotoxicity (Kristiansen et al. 2005). 
 
In this study, lectin-ELISA was employed to characterize the glycoform pattern on 
PrPC from young and aged mice brain. Results revealed enhanced complex sugar 
formation on full length PrPC and simultaneous simplification of truncated PrPC 
glycosylation. How and why such protein species-specific glycosylation occurs is 
unclear. However, these results lend strong support for a possible link between the 
glycosylation changes observed on PrPSc compared to PrPC, and that on PrPC as age 
increased. This is because enhanced complex glycan formation has also been reported 
on PrPSc compared to PrPC (Rudd et al. 1999). In addition, truncated PrPC with 
simplified sugar chains may also contribute to the pool of PrPSc species in prion 
disease, albeit in smaller proportions than aberrantly glycosylated full length PrPC. In 
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fact, recent two-dimensional gel electrophoresis of two different types of human 
sporadic prion disease revealed that the C1 N-truncated species were well represented 
in the detergent insoluble fraction from total PrP preparations, which is thought to 
comprise mostly PrPSc (Pan et al. 2001). PrPC undergoes endoproteolytic cleavage as 
part of its normal metabolism, resulting in a COOH-terminal fragment of PrPC 
designated C1. This fragment was present in both normal and CJD brains. On the 
other hand, a longer fragment termed C2 was found only in CJD brains (Chen et al. 
1995). However, because PK cleavage leaves a protease-resistant core of PrPSc from 
residues ~90 to 231, it becomes difficult to ascertain if and how these N-terminally 
truncated forms contribute to the PrPSc PK-resistant fragments. It is possible that 
ageing truncated PrPC may contribute to the pool of misfolded PrPSc and thus be 
retained in the ER for degradation via the ubiquitin-proteasome pathway. Such 
retention is corroborated by the reduction in complex sugar formation by Golgi-
resident glycosyltransferases (Figure 16B-16F), and an increased detection of 
mannose and glucose residues by ConA and LCA. Such N-glycans with high mannose 
and glucose residues are formed by ER-resident glycosyltransferases, hence 
suggesting failure of these ageing truncated PrPC to transit from the ER to the Golgi 
apparatus for further glycan modification to the complex type. Retention in the ER 
may result in overwhelming the proteasome and the consequent accumulation of 
ageing truncated PrPC may aid to seed further PrP aggregation culminating in 
neurotoxicity and cell death (Ma and Lindquist 2002). 
 
Figure 24 summarizes the observations from this current study and maps the possible 
sequence of events leading from variable PrP glycosylation to proteasomal 




Figure 24: Possible scheme of variable PrP glycosylation leading to proteasomal 
dysfunction in Prion disease 
Boxed up in blue are the observations from this current study. Similar observations in 
three strains of mouse prion disease (139A, ME7 and 22L) are highlighted in yellow 
(Pan et al. 2005b). Results from in vitro and in vivo studies have implicated 
proteasome dysfunction as the molecular mode of neurotoxicity and cell death in 
Prion disease (Kristiansen et al. 2005, 2007; Kang et al. 2004; Ma and Lindquist 
2002). 
 
Taken together, the results in this study indicate that although the mechanism 
underlying perturbed glycosylation in full length and truncated PrP remains to be 
resolved, its occurrence in both ageing and prion disease suggest that certain 
population of aberrantly glycosylated ageing PrPC may be preferentially susceptible to 
PrPSc pathogenic transition. As already discussed, ER retention is a means by which 
the PrP glycoform pattern may be altered. Other means by which ageing PrPC glycan 
structures can be modified include altered expression of glycosyltransferases and 
glycosidase, which are reported to be spatially and temporally regulated within the 
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tissue, altered enzymatic activities of glycosyltransferases and glycosidase and 
nucleotide-sugar substrate availability. It is important to establish the mechanism 
involved in the control of PrPC glycan biosynthesis before the age-related changes in 
PrPC glycosylation can be fully understood. 
 
6.2 FUTURE DIRECTIONS 
This study is largely a descriptive analysis of the glycan profile on neuronal PrPC 
during the ageing process. Prion research, however, will benefit tremendously if the 
association between the mechanism underlying the control of PrPC glycan 
biosynthesis and the changes on PrPC glycosylation can be unravelled. Thus far, it is 
unclear what specific structural characteristics of the age-related glycan species make 
them a temporal feature of PrPC. It can be speculated that the variations in the 
repertoires of specific sequences present in the different chains underlie their altered 
abilities to bind to pathogenic PrPSc, thereby modulating PrPC pathogenic conversion 
to PrPSc. Further studies will be required to isolate and elucidate the structures of 
these specific functional sequences. The first step would involve identifying the subtle 
alterations in the PrPC glycan profile that accompanies prion disease development. 
 
In this study, the glycosylation changes associated with ageing PrPC was inferred by 
lectin profiling of PrPC glycoform during ageing and the expression profiling of 
glycosyltranferases and glycosidases. However, these protein-based techniques 
exhibit limitations in terms of protein and tissue accessibility hence discouraging the 
detection of all fluctuations in sugar modifications. Fortunately, the recent interest and 
progress in glycobiology research has led to the advent of new and/or improved 
technologies for the study of glycan structural diversity and function. Described by 
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Prescher and Bertozzi (2005), the “bio-orthogonal chemical reporter” strategy exploits 
the physiological glycan biosynthetic machinery for the incorporation of detectable 
probes. Briefly, synthetic chemically inert azidosugars are incorporated into cellular 
glycans by the cell’s metabolic machinery and subsequently detected by fluorophores. 
Such glycan visualizations are analogous to protein visualization in vivo using green 
fluorescence-tagged proteins and would be beneficial for tracking the glycosylation 
changes associated with ageing PrPC in vivo. Using results from the current lectin 
profiling as a directional guide and combining with other strategies such as mass 
spectrometry (Petrescu et al. 2006), capable of detailing the structural information on 
glycans (including composition, glycosidic linkage and the identity of the underlying 
protein scaffolds), the “bio-orthogonal chemical reporter” strategy can potentially 
define a more complete structural assignment of ageing PrPC glycans and its 
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